<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0905245273
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Jemperli
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DOSTARLIMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27974.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AJINOMOTO ALTHEA INCORPORATED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AJINOMOTO ALTHEA INCORPORATED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>JEMPERLI contains the active substance dostarlimab, which is a <em>monoclonal antibody</em>, a type of protein designed to recognise and attach to a specific target substance in the body<em>.</em></p><p>JEMPERLI works by helping your immune system fight your cancer.</p><p>JEMPERLI is used in adults to treat a kind of cancer called <em>endometrial cancer </em>(cancer of the lining of the womb)<em>. </em>It is given when cancer has spread, or cannot be taken out by surgery, and has progressed on or following prior treatment.</p><p>JEMPERLI may be given in combination with other anticancer medicines. It is important that you also read the package leaflets for the other anticancer medicines you may be receiving. If you have any questions about these medicines, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given JEMPERLI:</strong><!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span>DOCVARIABLE vault_nd_45cfc54b-ee36-4fc7-a749-dd61a0fee76a
\* MERGEFORMAT<span style='mso-element:field-separator'></span></span><![endif]--><strong> </strong><!--[if supportFields]><b><span
style='font-size:12.0pt;mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to dostarlimab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong><!--[if supportFields]><span style='font-size:12.0pt;
mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>DOCVARIABLE
vault_nd_37f7bd3b-566a-495f-9f62-608a1ed81b67 \* MERGEFORMAT<span
style='mso-element:field-separator'></span></span><![endif]--><strong> </strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
11.0pt;mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Talk to your doctor or nurse before you are given JEMPERLI if you have:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immune system problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung or breathing problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver or kidney problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious rash;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any other medical problems.</p><p>&nbsp;</p><p><strong>Symptoms you need to look out for</strong></p><p>JEMPERLI can have serious side effects, which can sometimes become life‑threatening and can lead to death. These side effects may happen at any time during treatment, or even after your treatment has ended. You may get more than one side effect at the same time.</p><p>You need to be aware of possible symptoms, so your doctor can give you treatment for side effects if necessary.</p><p>&egrave;<strong>Read the information</strong> under &lsquo;Symptoms of serious side effects&rsquo; in section&nbsp;4. Talk to your doctor or nurse if you have any questions or worries.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>JEMPERLI should not be used in children and adolescents below 18&nbsp;years of age.</p><p>&nbsp;</p><p><strong>Other medicines and JEMPERLI</strong></p><p><strong>Tell your doctor or nurse</strong> if you are taking, have recently taken or might take any other medicines.</p><p>Some medicines may interfere with the effect of JEMPERLI:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that make your immune system weak &mdash; for example, <em>corticosteroids</em>, such as prednisone.</p><p>&agrave; <strong>Tell your doctor</strong> if you are taking any of these.</p><p>However, once you are treated with JEMPERLI, your doctor may give you corticosteroids to reduce any side effects that you may have.</p><p>&nbsp;</p><p><strong>Pregnancy</strong><!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span>DOCVARIABLE vault_nd_02725a76-4085-4fa8-b540-77a4a4f84060
\* MERGEFORMAT<span style='mso-element:field-separator'></span></span><![endif]--><strong> </strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>You must not be given JEMPERLI if you are pregnant</strong> unless your doctor specifically recommends it.<!--[if supportFields]><span style='font-size:12.0pt;
mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>DOCVARIABLE
vault_nd_408877f7-fa23-438e-8ab5-f682c40d45f6 \* MERGEFORMAT<span
style='mso-element:field-separator'></span></span><![endif]--> <!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-weight:bold;mso-no-proof:yes'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine.<!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span>DOCVARIABLE vault_nd_e0bf14ed-179a-40a3-ba33-294979729344
\* MERGEFORMAT<span style='mso-element:field-separator'></span></span><![endif]--> <!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-weight:bold;mso-no-proof:yes'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; JEMPERLI can cause harmful effects or death to your unborn baby.<!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span>DOCVARIABLE vault_nd_b5060855-821a-4103-806b-dd3fc076e68f
\* MERGEFORMAT<span style='mso-element:field-separator'></span></span><![endif]--> <!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-weight:bold;mso-no-proof:yes'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are a woman who could become pregnant, you must use effective <strong>contraception</strong> while you are being treated with JEMPERLI and for at least 4&nbsp;months after your last dose.<!--[if supportFields]><span style='font-size:12.0pt;mso-bidi-font-weight:
bold;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ab3e7c9c-6f91-478d-9005-f216c5a4d8c5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-weight:bold;mso-no-proof:yes'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Breast‑feeding</strong><!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span>DOCVARIABLE vault_nd_cc8a91ae-9c13-4cc0-8766-80b5cc7adb97
\* MERGEFORMAT<span style='mso-element:field-separator'></span></span><![endif]--><strong> </strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breast‑feeding, <strong>ask your doctor</strong> for advice before you are given this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>You must not breast‑feed</strong> during treatment and for at least 4&nbsp;months after your last dose of JEMPERLI.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is not known if the active ingredient of JEMPERLI passes into your breast milk.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong><!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><span style='mso-element:
field-begin'></span>DOCVARIABLE vault_nd_4f3d5423-f16b-4f03-8c1e-04bd4fd382c3
\* MERGEFORMAT<span style='mso-element:field-separator'></span></span><![endif]--><strong> </strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>JEMPERLI is unlikely to affect your ability to drive and use machines. However, if you have side effects that affect your ability to concentrate and react, you should be careful when driving or operating machines.</p><p><strong>&nbsp;</strong></p><p><strong>JEMPERLI contains sodium </strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dosage unit, that is to say essentially &lsquo;sodium‑free.&rsquo; However, before JEMPERLI is given to you, it is mixed with a solution that may contain sodium. Talk to your doctor if you are on a low salt diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>JEMPERLI will be given to you in a hospital or clinic under the supervision of a doctor experienced in cancer treatment.</p><p>When JEMPERLI is given on its own, the recommended dose of JEMPERLI is 500&nbsp;mg every 3&nbsp;weeks for 4&nbsp;doses, followed by 1000&nbsp;mg every 6&nbsp;weeks for all doses thereafter.</p><p>When JEMPERLI is given in combination with carboplatin and paclitaxel, the recommended dose of JEMPERLI is 500&nbsp;mg every 3&nbsp;weeks for 6&nbsp;doses, followed by 1000&nbsp;mg every 6&nbsp;weeks for all doses thereafter.</p><p>Your doctor will give you JEMPERLI as a drip into a vein <em>(intravenous infusion)</em> for about 30&nbsp;minutes.</p><p>Your doctor will decide how many treatments you need.</p><p><strong>If you forget an appointment to receive JEMPERLI</strong></p><p><strong>&egrave;</strong><strong> Contact your doctor or hospital</strong> <strong>immediately</strong> to reschedule your appointment.</p><p><strong>It is very important</strong> that you do not miss a dose of this medicine.</p><p>&nbsp;</p><p><strong>If you stop receiving JEMPERLI</strong></p><p>Stopping your treatment may stop the effect of the medicine. Do not stop treatment with JEMPERLI unless you have discussed this with your doctor.</p><p>&nbsp;</p><p><strong>Patient Card</strong></p><p>Important information from this Package Leaflet can be found in the Patient Card you have been given by your doctor. It is important that you keep this Patient Card and show it to your partner or caregivers.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Some of the side effects can be serious, and you need to know what symptoms to look out for.</p><p><strong>Symptoms of serious side effects</strong></p><p>JEMPERLI can cause serious side effects. If you develop symptoms <strong>you must tell your doctor or nurse as soon as possible.</strong> Your doctor may give you other medicines to prevent more serious complications and reduce your symptoms. Your doctor may decide that you should miss a dose of JEMPERLI, or stop your treatment altogether.</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Conditions</strong></p></td><td style="vertical-align:top"><p><strong>Possible symptoms</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Inflammation of lungs <em>(pneumonitis)</em></p></td><td style="vertical-align:top"><ul><li>shortness of breath</li></ul><ul><li>chest pain</li><li>new or worse cough</li></ul></td></tr><tr><td style="vertical-align:top"><p>Inflammation of intestines <em>(colitis, enteritis, vasculitis gastrointestinal)</em></p></td><td style="vertical-align:top"><ul><li>diarrhoea, or more bowel movements than usual</li><li>black, tarry, sticky stools; blood or mucus in stools</li><li>severe stomach pain or tenderness</li><li>feeling sick<em> (nausea)</em>, being sick <em>(vomiting)</em></li></ul></td></tr><tr><td style="vertical-align:top"><p>Inflammation of food pipe and stomach <em>(oesophagitis, gastritis)</em></p></td><td style="vertical-align:top"><ul><li>trouble swallowing</li><li>decreased appetite</li><li>burning in the chest (heartburn)</li><li>chest or upper belly pain</li><li>feeling sick (<em>nausea</em>), being sick (<em>vomiting</em>)</li></ul></td></tr><tr><td style="vertical-align:top"><p>Inflammation of liver <em>(hepatitis)</em></p></td><td style="vertical-align:top"><ul><li>feeling sick<em> (nausea)</em>, being sick <em>(vomiting)</em></li><li>loss of appetite</li><li>pain on the right side of the abdomen (stomach)</li><li>yellowing of the skin or the whites of the eyes</li><li>dark‑coloured urine</li><li>bleeding or bruising more easily than normal</li></ul></td></tr><tr><td style="vertical-align:top"><p>Inflammation of hormone glands <em>(especially thyroid, pituitary, adrenal, pancreas)</em></p></td><td style="vertical-align:top"><ul><li>rapid heartbeat</li><li>weight loss or weight gain</li><li>increased sweating</li><li>hair loss</li><li>feeling cold</li><li>constipation</li><li>abdominal pain</li><li>deeper voice</li><li>muscle aches</li><li>dizziness or fainting</li><li>headache that will not go away or unusual headache</li></ul></td></tr><tr><td style="vertical-align:top"><p>Type 1 diabetes, including diabetic ketoacidosis (acid in the blood produced from diabetes)</p><p>&nbsp;</p></td><td style="vertical-align:top"><ul><li>feeling more hungry or thirsty than usual</li><li>needing to urinate more often including at night</li><li>weight loss</li><li>feeling sick<em> (nausea)</em>, being sick <em>(vomiting)</em><em> </em></li><li>stomach pain</li><li>feeling tired</li><li>unusual sleepiness</li><li>having difficulty thinking clearly</li><li>breath that smells sweet or fruity</li><li>deep or fast breathing</li></ul></td></tr><tr><td style="vertical-align:top"><p>Inflammation of kidneys <em>(nephritis)</em></p></td><td style="vertical-align:top"><ul><li>changes in amount or colour of urine</li><li>swelling of the ankles</li><li>loss of appetite</li><li>blood in the urine</li></ul></td></tr><tr><td style="vertical-align:top"><p>Inflammation of skin</p></td><td style="vertical-align:top"><ul><li>rash, itching, dry skin, peeling or skin sores</li><li>ulcers in the mouth, nose, throat or genital area</li></ul></td></tr><tr><td style="vertical-align:top"><p>Inflammation of heart muscle <em>(myocarditis)</em></p></td><td style="vertical-align:top"><ul><li>trouble breathing</li><li>dizziness or fainting</li><li>fever</li><li>chest pain and chest tightness</li><li>flu like symptoms</li></ul></td></tr><tr><td style="vertical-align:top"><p>Inflammation of brain and nervous system <em>(myasthenic syndrome/myasthenia gravis, Guillain-Barr&eacute; syndrome, encephalitis)</em></p></td><td style="vertical-align:top"><ul><li>neck stiffness</li><li>headache</li><li>fever, chills</li><li>vomiting</li><li>eye sensitivity to light</li><li>weakness of eye muscles, drooping eyelids</li><li>dry eyes and blurred vision</li><li>difficulty swallowing, dry mouth</li><li>impaired speech</li><li>confusion and sleepiness</li><li>dizziness</li><li>pricking or pins and needles sensations in the hands and feet</li><li>aching muscles</li><li>difficulty walking or lifting objects</li><li>abnormal heart beat/rate or blood pressure</li></ul></td></tr><tr><td style="vertical-align:top"><p>Inflammation of spinal cord <em>(myelitis)</em></p></td><td style="vertical-align:top"><ul><li>pain</li><li>numbness</li><li>tingling, or weakness in the arms or legs</li><li>bladder or bowel problems including needing to urinate more frequently, urinary incontinence, difficulty urinating and constipation</li></ul></td></tr><tr><td style="vertical-align:top"><p>Inflammation of eyes</p></td><td style="vertical-align:top"><ul><li>changes in eyesight</li></ul></td></tr><tr><td style="vertical-align:top"><p>Inflammation of other organs</p></td><td style="vertical-align:top"><ul><li>severe or persistent muscle or joint pains</li><li>severe muscle weakness</li><li>swollen or cold hands or feet</li><li>feeling tired</li></ul></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Infusion‑related reactions</strong></p><p>Some people may have allergic‑like reactions when they receive an infusion. These usually develop within minutes or hours but may develop up to 24&nbsp;hours after treatment.</p><p>Symptoms include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath or wheezing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching or rash;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills or shaking;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drop in blood pressure (feeling like passing out).</p><p><strong>&nbsp;</strong></p><p><strong>Solid organ transplant rejection and other complications, including graft-versus-host disease (GvHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).</strong> These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with JEMPERLI. Your healthcare provider will monitor you for these complications.</p><p><strong>&egrave;</strong><strong> Seek medical attention immediately</strong> if you think you may be having a reaction.</p><p>&nbsp;</p><p>The following side effects have been reported with JEMPERLI alone.</p><p><strong>Very common side effects - </strong>(may affect <strong>more than 1 in 10</strong>&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of red blood cells <em>(anaemia);</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced thyroid gland activity;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea; feeling sick <em>(nausea)</em>; being sick <em>(vomiting);</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin redness or rash; blistering of the skin or mucous membranes; itchy skin;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high temperature; fever;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased liver enzyme levels in the blood.</p><p><strong>&egrave;</strong><strong> Check the table </strong>above for symptoms of possible serious side effects.</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects - </strong>(may affect <strong>up to 1 in 10</strong>&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; overactive thyroid gland;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased secretion of adrenal hormones <em>(adrenal insufficiency);</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lung;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lining of the bowel <em>(colon)</em>;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the stomach;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reaction to the infusion;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypersensitivity reaction to the infusion.</p><p><strong>&egrave;</strong><strong> Check the table </strong>above for symptoms of possible serious side effects.</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon side effects - </strong>(may affect <strong>up to 1 in 100&nbsp;</strong>people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the brain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; destruction of red blood cells (<em>Autoimmune haemolytic anaemia</em>);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pituitary gland, in the base of the brain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the thyroid gland;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Type 1 diabetes or diabetic complications <em>(diabetic ketoacidosis);</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the food pipe;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a condition in which the muscles become weak and there is a rapid fatigue of the muscles (<em>myasthenia gravis</em>);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the joints;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the muscles;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the eye &mdash; the iris (the coloured part of the eye) and the ciliary body (area around the iris);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the kidneys</p><p><strong>&egrave;</strong><strong> Check the table </strong>above for symptoms of possible serious side effects.</p><p>The following side effects have been reported with JEMPERLI when given in combination with carboplatin and paclitaxel.</p><p>&nbsp;</p><p><strong>Very common side effects - </strong>(may affect <strong>more than 1 in 10</strong>&nbsp;people):</p><ul><li>underactive thyroid gland</li><li>skin rash</li><li>dry skin</li><li>high temperature; fever</li><li>increased liver enzyme levels in the blood.</li></ul><p><strong>&egrave;</strong><strong> </strong><strong>Check the table </strong>above for symptoms of possible serious side effects.</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects - </strong>(may affect <strong>up to 1 in 10</strong>&nbsp;people):</p><ul><li>overactive thyroid gland</li><li>decreased secretion of adrenal hormones <em>(adrenal insufficiency)</em></li><li>inflammation of the lung</li><li>inflammation of the lining of the bowel <em>(colon)</em>.</li></ul><p><strong>&egrave;</strong><strong> Check the table </strong>above for symptoms of possible serious side effects.</p><p>&nbsp;</p><p><strong>Uncommon side effects - </strong>(may affect <strong>up to 1 in 100&nbsp;</strong>people):</p><ul><li>inflammation of the thyroid gland</li><li>Type 1 diabetes</li><li>a condition in which the muscles become weak and there is a rapid fatigue of the muscles (myasthenic syndrome)</li><li>inflammation of the heart muscle</li><li>inflammation of the pancreas</li><li>inflammation of the stomach</li><li>inflammation of the blood vessels in the food pipe, stomach or bowel</li><li>inflammation of the eye</li><li>inflammation of the joints</li><li>inflammation of the muscles</li><li>inflammation throughout the body.</li></ul><p><strong>&egrave;</strong><strong> Check the table </strong>above for symptoms of possible serious side effects.</p><p><strong>&egrave;</strong><strong> Contact your doctor or nurse as soon as possible</strong> if you develop any of these symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>JEMPERLI will be given to you in a hospital or clinic and the healthcare professionals will be responsible for its storage.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C). Do not freeze. Store in the original package in order to protect from light.</p><p>If not used immediately, the prepared infusion may be stored for up to 24&nbsp;hours at 2&nbsp;&deg;C to 8&nbsp;&deg;C or 6&nbsp;hours at room temperature (up to 25&nbsp;&deg;C) from the time of preparation/dilution until the end of administration.</p><p>Do not use if this medicine contains visible particles.</p><p>Do not store any unused medicine for reuse. Any unused medicine or waste material should be disposed of in accordance with local requirements. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is dostarlimab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One vial of 10&nbsp;mL concentrate for solution for infusion (sterile concentrate) contains 500&nbsp;mg of dostarlimab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each mL of concentrate for solution for infusion contains 50&nbsp;mg of dostarlimab.</p><p>The other ingredients are trisodium citrate dihydrate; citric acid monohydrate; L‑arginine hydrochloride; sodium chloride; polysorbate&nbsp;80; and water for injection (see section&nbsp;2).</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p><strong>The following information is intended for healthcare professionals only:</strong></p><p>Preparation/dilution, storage and administration of the solution for infusion:</p><p>&middot; Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. JEMPERLI is a slightly opalescent colourless to yellow solution. Discard the vial if visible particles are observed.</p><p>&middot;&nbsp;&nbsp;JEMPERLI is compatible with an IV bag made of polyvinyl chloride (PVC) with or without di(2-ethylhexyl) phthalate (DEHP), ethylene vinyl acetate, polyethylene (PE), polypropylene (PP) or polyolefin blend (PP+PE), and a syringe made from PP.</p><p>&middot; For the 500 mg dose, withdraw 10&nbsp;mL of JEMPERLI from a vial and transfer into an intravenous bag containing sodium chloride 9&nbsp;mg/mL (0.9&nbsp;%) solution for injection or glucose 50&nbsp;mg/mL (5&nbsp;%) solution for injection. The final concentration of the diluted solution should be between 2&nbsp;mg/mL and 10&nbsp;mg/mL. This may require withdrawing a volume of diluent from the IV bag prior to adding a volume of JEMPERLI into the IV bag.</p><p>- For example, if preparing a 500 mg dose in a 250 mL diluent IV bag, to achieve a 2&nbsp;mg/mL concentration would require withdrawing 10 mL of diluent from the 250 mL IV bag. Then, 10 mL of JEMPERLI would be withdrawn from the vial and transferred into the IV bag.</p><p>&middot;&nbsp; For the 1000&nbsp;mg dose, withdraw 10&nbsp;mL of JEMPERLI from each of two vials (withdraw 20&nbsp;mL total) and transfer into an intravenous bag containing sodium chloride 9&nbsp;mg/mL (0.9&nbsp;%) solution for injection or glucose 50&nbsp;mg/mL (5&nbsp;%) solution for injection. The final concentration of the diluted solution should be between 2&nbsp;mg/mL and 10&nbsp;mg/mL. This may require withdrawing a volume of diluent from the IV bag prior to adding a volume of JEMPERLI into the IV bag.</p><p>-&nbsp; For example, if preparing a 1000 mg dose in a 500 mL diluent IV bag, to achieve a 2&nbsp;mg/mL concentration would require withdrawing 20 mL of diluent from the 500 mL IV bag. Then, 10 mL of JEMPERLI would be withdrawn from each of two vials, totaling 20&nbsp;mL, and transferred into the IV bag.</p><p>&middot; Mix diluted solution by gentle inversion. Do not shake the final infusion bag. Discard any unused portion left in the vial.</p><p>&middot;&nbsp;Store in the original carton until time of preparation in order to protect from light. The prepared dose may be stored either:</p><p>-&nbsp;At room temperature up to 25&nbsp;&ordm;C for no more than 6&nbsp;hours from the time of dilution until the end of infusion.</p><p>- Under refrigeration at 2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C for no more than 24&nbsp;hours from time of dilution until end of infusion. If refrigerated, allow the diluted solution to come to room temperature prior to administration.</p><p>&middot;&nbsp; JEMPERLI should be administered by intravenous infusion using an intravenous infusion pump over 30&nbsp;minutes by a health care practitioner.</p><p>&middot; Tubing should be made of PVC, platinum cured silicon or PP; fittings made from PVC or polycarbonate and needles made from stainless steel.</p><p>&middot;&nbsp;A 0.2 or 0.22 micron in-line polyethersulfone (PES) filter must be used during administration of JEMPERLI.</p><p>&middot;&nbsp; JEMPERLI must not be administered as an intravenous push or bolus injection.</p><p>&middot;&nbsp; Do not co‑administer other medicinal products through the same infusion line.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                JEMPERLI is a clear to slightly opalescent colourless to yellow solution, essentially free from visible particles.
It is available in cartons containing one glass vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>Ajinomoto Althea, Inc.(dba Ajinomoto Bio-Pharma Services), 11040 Roselle Street, San Diego, CA 92121, USA</p><p><strong>Packed by:</strong></p><p>Packaging Coordinators, LLC, 3001 Red Lion Road, Philadelphia, PA, 19114, USA</p><p><strong>Release by:</strong></p><p>GlaxoSmithKline LLC, 1011 North Arendell, Avenue, Zebulon, NC 27597, USA</p><p><strong>Marketing Authorisation Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia</p><p>*member of the GlaxoSmithKline group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version number: EMA-v08 
Date of revision of the text: 07 December 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي دواء جيمپيرلي على المادة الفعالة دوستارليماب، وهي عبارة عن جسم مضاد أحادي النسيلة، ويعد نوع من البروتين المصمم للتعرف على<strong> </strong>مادة مستهدفة محددة في الجسم والالتصاق بها.</p><p dir="RTL">يعمل دواء جيمپيرلي من خلال مساعدة جهاز المناعة لديك على محاربة السرطان.</p><p dir="RTL">يستخدم دواء جيمپيرلي في البالغين لعلاج أحد أنواع السرطان؛ يسمى سرطان بطانة الرحم. يُعطى عند انتشار السرطان، أو الذي لا يمكن إزالته عن طريق الجراحة، أو في المراحل المتقدمة، أو بعد تلقي العلاج المسبق.</p><p dir="RTL">يمكن تلقي جيمبرلي مع غيره من الأدوية المعالجة للسرطان، لذلك من المهم أن تقرأ أيضًا نشرات عبوات الأدوية الأخرى المعالجة للسرطان التي قد تتلقاها. إذا كان لديك أي أسئلة عن هذه الأدوية، اطرحها على طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم تناول دواء جيمپيرلي: </strong></p><p dir="RTL">إذا كان لديك رد فعل تحسسي تجاه مادة دوستارليماب أو أي من المواد الفعالة الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك المعالج أو ممرضتك قبل أن تتلقى دواء جيمپيرلي إذا كنت تعاني من:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في جهاز المناعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الرئة أو التنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكبد أو الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي خطير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي مشاكل طبية أخرى.</p><p dir="RTL"><strong>يجب توخي الحذر عند ظهور بعض الأعراض</strong></p><p dir="RTL">يمكن أن يُسبب دواء جيمپيرلي آثار جانبية خطيرة، والتي يمكن أن تهدد الحياة في بعض الأحيان، أو تؤدي إلى الوفاة. يمكن أن تحدث هذه الآثار الجانبية في أي وقت أثناء العلاج، أو حتى بعد انتهاء العلاج، ويمكن أن تصاب بأكثر من عرض جانبي في نفس الوقت.</p><p dir="RTL">يجب أن تكون على دراية بالأعراض المحتمل حدوثها، حتى يتمكن طبيبك المعالج من إعطائك علاجًا للآثار الجانبية إذا لزم الأمر.</p><p dir="RTL">&ccedil; <strong>يرجى قراءة المعلومات الموجودة</strong> تحت &quot;أعراض الآثار الجانبية الخطيرة&quot; في القسم 4. تحدث إلى طبيبك المعالج أو ممرضتك إذا كانت لديك أية أسئلة أو مخاوف.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينبغي استخدام دواء جيمپيرلي للأطفال أو المراهقين الذين تقل أعمارهم عن 18 عامًا.</p><p dir="RTL"><strong>جيمپيرلي والأدوية الأخرى</strong></p><p dir="RTL"><strong>يرجى إبلاغ الطبيب المعالج أو الممرضة</strong> إذا كنت تتناول أي أدوية أخرى، أو إذا تناولت أي أدوية في الآونة الأخيرة، أو إذا بدأت في تناول أدوية جديدة.</p><p dir="RTL">يمكن أن يحدث تداخل بين بعض الأدوية مع تأثير دواء جيمپيرلي:</p><p dir="RTL">&bull; الأدوية التي تضعف جهاز المناعة لديك -على سبيل المثال، <em>الكورتيكوستيرويدات</em>، مثل بريدنيزون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&ccedil;<strong> </strong><strong>يرجي إبلاغ طبيبك المعالج</strong> إذا كنت تتناول أيًا من هذه الأدوية.</p><p dir="RTL">ومع ذلك، بمجرد أن تُعالج بدواء جيمپيرلي، يمكن أن يعطيك طبيبك الكورتيكوستيرويدات لتقليل أي آثار جانبية قد تحدث لك.</p><p dir="RTL"><strong>الحمل </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يجب عدم تلقي دواء جيمپيرلي في حالة الحمل؛</strong> إلا إذا أوصى طبيبكِ المعالج بذلك على وجه التحديد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً، أو تعتقدي أنكِ قد تكونين حاملًا، أو إذا كنتِ تخططين لإنجاب طفل، فتحدثي مع الطبيب المعالج للحصول على المشورة قبل تلقي هذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يسبب دواء جيمپيرلي آثارًا ضارة أو الموت لجنينك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة احتمال حدوث الحمل، فيجب عليكِ استخدام وسيلة فعالة <strong>لمنع الحمل</strong> أثناء فترة علاجكِ بدواء جيمپيرلي، ولمدة 4 أشهر على الأقل بعد آخر جرعة.</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الرضاعة الطبيعية، <strong>استشيري طبيبكِ المعالج</strong> للحصول على المشورة قبل إعطائكِ هذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يجب عدم الرضاعة الطبيعية</strong> أثناء العلاج ولمدة 4 أشهر على الأقل بعد آخر جرعة من دواء جيمپيرلي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من غير المعروف ما إذا كانت المادة الفعالة من جيمپيرلي يمكن أن تفرز في حليب الثدي.</p><p dir="RTL"><strong>قيادة السيارة واستخدام الآلات</strong></p><p dir="RTL">من غير المتوقع أن يؤثر دواء جيمپيرلي على قدرتك على القيادة أو استخدام الآلات. ومع ذلك، إذا كنت تعاني من آثار جانبية تؤثر على قدرتك على التركيز والتفاعل، فيجب أن تكون حذرًا عند القيادة أو تشغيل الآلات.</p><p dir="RTL"><strong>يحتوي دواء جيمپيرلي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ملي مول من الصوديوم (23 ملجم) لكل جرعة واحدة، وهذا يعني بشكل أساسي &quot;خالٍ من الصوديوم&quot;. ومع ذلك، قبل إعطاء دواء جيمپيرلي لك، يتم مزجه مع محلول قد يحتوي على الصوديوم. تحدث إلى طبيبك المعالج إذا كنت تتبع نظامًا غذائيًا قليل الملح.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ستتلقى دواء جيمپيرلي في مستشفى أو عيادة تحت إشراف طبيب خبير في علاج السرطان.</p><p dir="RTL">عند تلقي جيمپيرلي بمفرده، فإن الجرعة الموصى بها من دواء جيمپيرلي هي 500 ملجم كل 3 أسابيع للجرعات الأربعة الأولى، ثم تكون بعد ذلك 1000 ملجم كل 6 أسابيع لجميع الجرعات.</p><p dir="RTL">عند تلقي جيمبرلي مع كاربوبلاتين وباكليتاكسيل، فإن الجرعة الموصى بها من جيمبرلي هي 500 ملغم كل 3 أسابيع لـ 6 جرعات، تليها 1000 ملغم كل 6 أسابيع لجميع الجرعات بعد ذلك.</p><p dir="RTL">سيعطيك طبيبك المعالج دواء جيمپيرلي بالتنقيط في الوريد (<em>التسريب الوريدي</em>) لمدة 30 دقيقة تقريبًا.</p><p dir="RTL">سيقرر طبيبك المعالج عدد جرعات العلاج التي تحتاجها.</p><p dir="RTL"><strong>في حالة نسيان موعد تلقي جرعة دواء جيمپيرلي</strong></p><p dir="RTL">&ccedil; <strong>يجب الاتصال بالطبيب المعالج أو المستشفى على الفور</strong>؛ وذلك لإعادة جدولة موعد الجرعات الفائتة.</p><p dir="RTL"><strong>من المهم جدًا</strong> ألا تفوت جرعة من هذا الدواء.</p><p dir="RTL"><strong>إذا توقفت عن تلقي دواء جيمپيرلي</strong></p><p dir="RTL">وقف العلاج يمكن أن يوقف تأثير الدواء. لا تتوقف عن العلاج بدواء جيمپيرلي إلا إذا ناقشت هذا الأمر مع طبيبك.</p><p dir="RTL"><strong>بطاقة المريض</strong></p><p dir="RTL">يمكن العثور على معلومات هامة من هذه النشرة الداخلية في بطاقة المريض التي أعطاها لك طبيبك المعالج. من المهم أن تحتفظ ببطاقة المريض، وأن تعرضها على شريكك أو مقدمي الرعاية.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، استشر طبيبك المعالج أو ممرضتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">يمكن أن تكون بعض الآثار الجانبية خطيرة، وتحتاج إلى معرفة الأعراض التي يجب توخي الحذر منها.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض الآثار الجانبية الخطيرة</strong></p><p dir="RTL">يمكن أن يسبب دواء جيمپيرلي آثارًا جانبية خطيرة. <strong>إذا ظهرت عليك أي أعراض؛ يجب عليك إخبار طبيبك المعالج أو ممرضتك في أسرع وقت ممكن.</strong> يمكن أن يعطيك طبيبك أدوية أخرى لمنع حدوث مضاعفات أكثر خطورة وتقليل الأعراض، ويقرر أنه يجب عليك تفويت جرعة من دواء جيمپيرلي، أو التوقف عن العلاج تمامًا.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الحالات </strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الأعراض المحتملة </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب رئوي</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال جديد أو تفاقمه</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الأمعاء والقولون، التهاب الأوعية الدموية للجهاز الهضمي</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، أو زيادة حركات الأمعاء أكثر من المعتاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز أسود، وقطراني، ولزج، مع وجود دم أو مخاط في البراز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في المعدة أو ألم عند اللمس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان أو القيء</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب المريء والمعدة</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرق في الصدر (حرقة في المعدة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر أو أعلى البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان أو القيء</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الكبد</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان أو القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الجانب الأيمن من البطن (المعدة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد، أو بياض العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البول ذو اللون الداكن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث نزيف أو كدمات بسهولة أكثر من المعتاد</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الغدد الهرمونية (خاصة الغدة الدرقية والغدة النخامية والكظرية والبنكرياس)</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن أو زيادته</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالبرد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خشونة الصوت</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة أو الإغماء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع مستمر أو صداع غير عادي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">داء السكري من النوع الأول، ويشمل الحماض الكيتوني السكري (انتاج حمض في الدم من مرض السكري)</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالجوع أو العطش أكثر من المعتاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحاجة إلى التبول في كثير من الأحيان بما في ذلك أثناء الليل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان أو القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس غير عادي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود صعوبة في التفكير بوضوح</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رائحة النفس التي تفوح منها رائحة حلوة أو شبيهة بالفاكهة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنفس العميق أو السريع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الكلى</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في كمية البول أو لونه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الكاحلين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في البول</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الجلد</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو حكة أو جفاف الجلد أو تقشير الجلد أو تقرحه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات في الفم أو الأنف أو الحلق أو منطقة الأعضاء التناسلية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب عضلة القلب</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة أو الإغماء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر وضيق في الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعراض تشبه اعراض الانفلونزا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الدماغ والجهاز العصبي (متلازمة الوهن العضلي / الوهن العضلي الوبيل، متلازمة غيلان باريه، التهاب الدماغ)</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب الرقبة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى وقشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية العين للضوء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف عضلات العين وتدلي الجفون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العين وضعف الرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع وجفاف الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الكلام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك والنعاس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالوخز أو الدبابيس والإبر في اليدين والقدمين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في المشي أو رفع الأشياء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في ضربات/ معدل القلب أو ضغط دم غير الطبيعي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب النخاع الشوكي</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو ضعف في الذراعين أو الساقين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في المثانة أو الأمعاء، تشمل الحاجة إلى التبول بشكل متكرر، وسلس البول، وصعوبة التبول، والإمساك</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب العينين</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في البصر</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب الأعضاء الأخرى</p></td><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام شديدة أو مستمرة في العضلات أو المفاصل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف شديد في العضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم أو برودة اليدين أو القدمين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب</p></td></tr></tbody></table><p dir="RTL"><strong>ردود الفعل المرتبطة بالتسريب الوريدي</strong></p><p dir="RTL">يمكن أن يعاني بعض الأشخاص من ردود فعل تشبه الحساسية عند تلقى محلول بالتسريب الوريدي. وتظهر هذه الأعراض عادةً في غضون دقائق أو ساعات ولكنها قد تتطور حتى 24 ساعة بعد العلاج</p><p dir="RTL">تشمل الأعراض:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس أو صفير</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة أو طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة أو اهتزاز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في ضغط الدم (شعور يشبه فقدان الوعي).</p><p dir="RTL"><strong>رفض زرع الأعضاء الصلبة والمضاعفات الأخرى، بما في ذلك عدم توافق الخلايا مع المضيف، في الأشخاص الذين أجروا عملية زرع نخاع العظم (الخلايا الجذعية) التي تستخدم الخلايا الجذعية من متبرع (خيفي).</strong> يمكن أن تكون هذه المضاعفات خطيرة، ويمكن أن تؤدي إلى الوفاة. قد تحدث هذه المضاعفات إذا خضعت لعملية زرع إما قبل العلاج أو بعده بدواء جيمپيرلي سيراقبك مقدم الرعاية الصحية للتغلب على هذه المضاعفات.</p><p dir="RTL">&ccedil; <strong>اطلب العناية الطبية على الفور</strong> إذا كنت تعتقد أنك تعاني من رد فعل تحسسي.</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية عند تلقي دواء جيمپيرلي بمفرده.</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا</strong>-(قد تظهر لدى أكثر من <strong>1 من كل 10</strong> أشخاص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نشاط الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال، والغثيان، وقيء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد أو الطفح الجلدي. تقرحات في الجلد أو الأغشية المخاطية، مع حكة في الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة، حمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات إنزيمات الكبد في الدم</p><p dir="RTL"><strong>&ccedil;</strong><strong> </strong><strong>يرجى مراجعة الجدول</strong> الموضح أعلاه للتعرف على أعراض الآثار الجانبية الخطيرة المحتملة</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong> -(قد تظهر لدى <strong>حتى 1 من كل 10</strong> أشخاص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض إفراز هرمونات الغدة الكظرية (قصور الغدة الكظرية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة الأمعاء (القولون)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي تجاه التسريب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحساسية تجاه التسريب</p><p dir="RTL"><strong>&ccedil;</strong><strong> </strong><strong>يرجى مراجعة الجدول</strong> الموضح أعلاه للتعرف على أعراض الآثار الجانبية الخطيرة المحتملة.</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> - (قد تظهر لدى حتى 1<strong> من كل 100</strong> شخص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الدماغ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدمير خلايا الدم الحمراء (فقر الدم الانحلالي ذاتي المناعة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغدة النخامية في قاعدة الدماغ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري من النوع الأول أو مضاعفاته (الحماض الكيتوني السكري)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المريء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة تضعف فيها العضلات ويحدث إجهاد سريع للعضلات (الوهن العضلي الوبيل)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين -القزحية (الجزء الملون من العين) والجسم الهدبي (المنطقة المحيطة بالقزحية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلتين.</p><p dir="RTL"><strong>&ccedil;</strong><strong> </strong><strong>يرجى مراجعة الجدول</strong> الموضح أعلاه للتعرف على أعراض الآثار الجانبية الخطيرة المحتملة.</p><p dir="RTL">وقد أُبلغ عن الآثار الجانبية التالية مع جيمبرلي عند إعطائه مع الكاربوبلاتين والباكليتاكسيل.</p><p dir="RTL"><strong>أعراض جانبية شائعة جدًا - </strong>(قد تظهر على أكثر من<strong> شخص من كل 10</strong> أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خمول الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة، حمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستويات إنزيمات الكبد في الدم</p><p dir="RTL"><strong>&ccedil;</strong><strong> يرجى مراجعة الجدول</strong> الموضح أعلاه للتعرف على أعراض الآثار الجانبية الخطيرة المحتملة.</p><p dir="RTL"><strong>الآثار الجانبية الشائعة -(قد تظهر لدى حتى 1 من كل 10 أشخاص):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض إفراز هرمونات الغدة الكظرية (قصور الغدة الكظرية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة الأمعاء (القولون)</p><p dir="RTL"><strong>&ccedil;</strong><strong> يرجى مراجعة الجدول</strong> الموضح أعلاه للتعرف على أعراض الآثار الجانبية الخطيرة المحتملة</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> - (قد تظهر لدى حتى 1<strong> من كل 100</strong> شخص):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغدة الدرقية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري من النوع الأول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة تصبح فيها العضلات ضعيفة يصاحبها إرهاق سريع للعضلات (متلازمة الوهن العضلي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب عضلة القلب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية في مجرى الطعام أو المعدة أو الأمعاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في جميع أنحاء الجسم.</p><p dir="RTL"><strong>&ccedil;</strong><strong> يرجى مراجعة الجدول</strong> الموضح أعلاه للتعرف على أعراض الآثار الجانبية الخطيرة المحتملة</p><p dir="RTL"><strong>&ccedil; يرجى الاتصال بطبيبك المعالج أو ممرضتك في أقرب وقت ممكن</strong>؛ إذا ظهرت عليك أي من هذه الأعراض</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاء دواء جيمپيرلي لك في مستشفى أو عيادة، ويتولى متخصصون الرعاية الصحية مسؤولية تخزين هذا الدواء.</p><p dir="RTL">يحفظ بعيدًا عن نظر ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على ملصق العبوة الكرتون والڤيال بعد كلمة EXP.</p><p dir="RTL">يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">يُخزن في الثلاجة (في درجة حرارة بين 2 و8 درجة مئوية). لا يجمد. يُخزن في عبوته الأصلية لحمايته من الضوء.</p><p dir="RTL">إذا لم يتم استخدامه على الفور، يمكن تخزين محلول التسريب المحضر لمدة تصل إلى 24 ساعة عند 2 درجة مئوية إلى 8 درجات مئوية أو 6 ساعات في درجة حرارة الغرفة (حتى 25 درجة مئوية) من وقت التحضير/ التخفيف حتى نهاية الإعطاء.</p><p dir="RTL">لا يُستخدم هذا الدواء إذا كان يحتوي على جزيئات مرئية.</p><p dir="RTL">لا تخزن أي دواء غير مستعمل لإعادة استخدامه مرة أخرى. يجب التخلص من أي دواء أو نفايات غير مستخدمة وفقًا للمتطلبات المحلية. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي على المادة الفعالة: دوستارليماب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي ڤيال واحد على 10 مل من محلول التسريب (مركز معقم) على تركيز 500 ملجم من دوستارليماب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل 1 مل من محلول التسريب على تركيز 50 ملجم دوستارليماب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي ثلاثي سترات الصوديوم ثنائي هيدرات. أحادي هيدرات حامض الستريك؛ ل-ارجينين هيدروكلوريد، كلوريد الصوديوم، بولي سوربات 80، وماء للحقن (انظر القسم 2).</p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p dir="RTL"><strong>المعلومات التالية مخصصة لمتخصصي الرعاية الصحية فقط:</strong></p><p dir="RTL">تحضير/ تخفيف وتخزين وإعطاء محلول التسريب:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب فحص المنتجات الطبية التي تُعطى عن طريق الحقن بصريًا بحثًا عن وجود أي جسيمات أو تغير في اللون قبل الإعطاء. دواء جيمپيرلي هو محلول عديم اللون مائل إلى الأصفر براق قليلاً. يجب التخلص من الڤيال إذا لاحظت وجود جسيمات مرئية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوافق دواء جيمپيرلي مع الكيس الوريدي المصنوع من البولي فينيل كلوريد مع ثنائي (2-إيثيل هكسيل) فثالات، وأسيتات فينيل الإيثلين، والبولي إيثيلين، والبولي بروبيلين أو مزيج من البولي أوليفين (PP+PE)، وحقنة مصنوعة من البولي بروبيلين PP.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة لجرعة بتركيز 500 ملجم، اسحب 10 مل من دواء جيمپيرلي من الڤيال وانقلها إلى كيس وريدي يحتوي على محلول كلوريد الصوديوم 9 ملجم/ مل (0.9٪) للحقن أو محلول جلوكوز 50 ملجم/ مل (5٪) للحقن. يجب أن يكون التركيز النهائي للمحلول المخفف بين 2 ملجم/ مل و10 ملجم/ مل. يمكن أن يتطلب ذلك سحب كمية من المادة المخففة من كيس السوائل الوريدية قبل إضافة حجم دواء جيمپيرلي في كيس السوائل الوريدية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; على سبيل المثال، في حالة تحضير جرعة بتركيز 500 ملجم في كيس وريدي يحتوي على المادة المخففة بحجم 250 مل، فإن تحقيق تركيز 2 ملجم/ مل يتطلب سحب 10 مل من المادة المخففة من الكيس الوريدي الذي يحتوي على 250 مل. بعد ذلك، سيتم سحب 10 مل من دواء جيمپيرلي من الڤيال ونقلها إلى الكيس الوريدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة لجرعة بتركيز 1000 ملجم، اسحب 10 مل من دواء جيمپيرلي من كل اثنان من الڤيال (اسحب 20 مل إجمالاً) وانقلها إلى الكيس الوريدي الذي يحتوي على محلول كلوريد الصوديوم 9 ملجم/ مل (0.9٪) للحقن أو محلول الجلوكوز 50 ملجم/ مل (5٪) للحقن. يجب أن يكون التركيز النهائي للمحلول المخفف بين 2 ملجم / مل و10 ملجم / مل. يمكن أن يتطلب ذلك سحب كمية من المادة المخففة من كيس السوائل الوريدية قبل إضافة حجم دواء جيمپيرلي في كيس السوائل الوريدية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; على سبيل المثال، في حالة تحضير جرعة بتركيز 1000 ملجم في كيس وريدي يحتوي على المادة المخففة بحجم 500 مل، فإن تحقيق تركيز 2 ملجم / مل يتطلب سحب 20 مل من المادة المخففة من الكيس الوريدي الذي يحتوي على 500 مل. بعد ذلك، سيتم سحب 10 مل من دواء جيمپيرلي من كل من اثنان من الڤيال، بإجمالي 20 مل، ونقلها إلى الكيس الوريدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اخلط المحلول المخفف عن طريق التقليب بلطف. لا تهز كيس التسريب النهائي. ويجب التخلص من أي جزء غير مستخدم متبقي في الڤيال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب التخزين في العبوة الأصلية حتى وقت التحضير وذلك لحمايته من الضوء. يمكن تخزين الجرعة المحضرة إما:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند درجة حرارة الغرفة حتى 25 درجة مئوية لمدة لا تزيد عن 6 ساعات من وقت التخفيف حتى نهاية التسريب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الثلاجة عند 2 درجة مئوية حتى 8 درجات مئوية لمدة لا تزيد عن 24 ساعة من وقت التخفيف حتى نهاية التسريب. في حالة التبريد، يجب ترك المحلول المخفف حتى يصل إلى درجة حرارة الغرفة قبل الإعطاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب إعطاء دواء جيمپيرلي عن طريق التسريب في الوريد باستخدام مضخة التسريب الوريدي لمدة 30 دقيقة بواسطة ممارس الرعاية الصحية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تُصنع الأنابيب من بولي كلوريد الفينيل أو السيليكون المعالج بالبلاتين أو البولي بروبيلين؛ والوصلات من بولي كلوريد الفينيل أو بولي كربونات، والإبر من الفولاذ المقاوم للصدأ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب استخدام جهاز ترشيح بقياس 0.2 أو 0.22 ميكرون من البولي إيثر سلفون الخطي (PES) أثناء إعطاء دواء جيمپيرلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجب إعطاء دواء جيمپيرلي كدفعة في الوريد أو الحقن الوريدي الفوري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجب إعطاء المنتجات الطبية الأخرى من خلال نفس خط التسريب.</p><p dir="RTL">يجب التخلص من أي منتج طبي أو نفايات غير مستخدمة وفقًا للمتطلبات المحلية.</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دواء جيمپيرلي عبارة عن سائل شفاف، عديم اللون مائل إلى الأصفر براق قليلاً، خالي بشكل أساسي من الجسيمات المرئية.</p><p dir="RTL">متوفر في عبوة من الكرتون تحتوي على ڤيال زجاجي واحد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع:</strong></p><p dir="RTL">أجينوموتو ألثيا إنك. (دي بي أيه أجينوموتو بايوفارما سيرفيسز) 11040 شارع روسيلي، سان دييغو، كاليفورنيا 92121، الولايات المتحدة الأمريكية</p><p dir="RTL"><strong>تعبئة:</strong></p><p dir="RTL">منسقو التعبئة والتغليف، إل إل سي 3001 طريق الريد ليون، فبلادلفيا، بنسلفانيا 19114، الولايات المتحدة الأمريكية</p><p dir="RTL"><strong>الإفراج النهائي:</strong></p><p dir="RTL">جلاكسو سميث كلاين إل إل سي 1011 شارع نورث أرنديل، زيبليون، كارولاينا الشمالية 27597، الولايات المتحدة الأمريكية</p><p dir="RTL"><strong>تسويق:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، المملكة العربية السعودية.</p><p dir="RTL">العنوان: ص.ب 22617، جدة، 21416، المملكة العربية السعودية.</p><p dir="RTL">* عضو في مجموعة شركات جلاكسو سميث كلاين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم الإصدار: EMA-v08
تاريخ مراجعة النص:7 ديسمبر 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                JEMPERLI 500 mg concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial of 10 mL concentrate for solution for infusion contains 500 mg of dostarlimab.

Each mL of concentrate for solution for infusion contains 50 mg of dostarlimab. 

Dostarlimab is an anti programmed cell death protein 1 (PD 1) immunoglobulin G4 (IgG4) humanised monoclonal antibody (mAb), produced by recombinant DNA technology in mammalian Chinese hamster ovary (CHO) cells.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion (sterile concentrate). 

Clear to slightly opalescent colourless to yellow solution, essentially free from visible particles. 

The concentrate for solution for infusion has a pH of approximately 6.0 and an osmolality of approximately 300 mOsm/kg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability high (MSI H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.</p><p>JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI H recurrent or advanced EC that has progressed on or following prior treatment with a platinum containing regimen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy must be initiated and supervised by specialist physicians experienced in the treatment of cancer.</p><p>The identification of dMMR/MSI-H tumour status should be determined using a validated testing method such as IHC, PCR or NGS* (see section&nbsp;5.1 for information on assays used in the studies).</p><p>*IHC=immunohistochemistry; PCR=polymerase chain reaction; NGS=next-generation sequencing.</p><p><u>Posology</u></p><p><em>JEMPERLI in combination with carboplatin and paclitaxel</em></p><p>When JEMPERLI is administered in combination with carboplatin and paclitaxel, refer to the full Prescribing Information for the combination products (see also section 5.1).</p><p>The recommended dose is 500&nbsp;mg dostarlimab every 3 weeks in combination with carboplatin and paclitaxel every 3 weeks for 6 cycles followed by 1000 mg dostarlimab as monotherapy every 6 weeks for all cycles thereafter.</p><p>The dosage regimen in combination with carboplatin and paclitaxel is presented in Table 1.</p><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Table 1. Dosage regimen for JEMPERLI</strong><strong> in combination with carboplatin and paclitaxel</strong></p><p><img alt="" width="782" height="220" src="data:image/png;base64,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" /></p><p><sup>a</sup> Administer dostarlimab prior to carboplatin and paclitaxel on the same day.</p><p><em>&nbsp;</em></p><p>Administration of dostarlimab should continue according to the recommended schedule until disease progression or unacceptable toxicity, or for a duration of up to 3 years (see section 5.1).</p><p><em>&nbsp;</em></p><p><em><u>JEMPERLI monotherapy</u></em></p><p>The recommended dose as monotherapy is 500&nbsp;mg dostarlimab every 3&nbsp;weeks for 4&nbsp;cycles followed by 1000&nbsp;mg every 6&nbsp;weeks for all cycles thereafter.</p><p>The dosage regimen as monotherapy is presented in Table&nbsp;2.</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;2. Dosage regimen for JEMPERLI </strong><strong>as monotherapy</strong></p><p><strong><img alt="" width="806" height="227" src="data:image/png;base64,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" /></strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t87" coordsize="21600,21600"
 o:spt="87" adj="1800,10800" path="m21600,qx10800@0l10800@2qy0@11,10800@3l10800@1qy21600,21600e"
 filled="f">
 <v:formulas>
  <v:f eqn="val #0"/>
  <v:f eqn="sum 21600 0 #0"/>
  <v:f eqn="sum #1 0 #0"/>
  <v:f eqn="sum #1 #0 0"/>
  <v:f eqn="prod #0 9598 32768"/>
  <v:f eqn="sum 21600 0 @4"/>
  <v:f eqn="sum 21600 0 #1"/>
  <v:f eqn="min #1 @6"/>
  <v:f eqn="prod @7 1 2"/>
  <v:f eqn="prod #0 2 1"/>
  <v:f eqn="sum 21600 0 @9"/>
  <v:f eqn="val #1"/>
 </v:formulas>
 <v:path arrowok="t" o:connecttype="custom" o:connectlocs="21600,0;0,10800;21600,21600"
  textboxrect="13963,@4,21600,@5"/>
 <v:handles>
  <v:h position="center,#0" yrange="0,@8"/>
  <v:h position="topLeft,#1" yrange="@9,@10"/>
 </v:handles>
</v:shapetype><v:shape id="Left_x0020_Brace_x0020_6" o:spid="_x0000_s1027"
 type="#_x0000_t87" style='position:absolute;margin-left:228.15pt;margin-top:65.6pt;
 width:18.6pt;height:61.1pt;rotation:-90;z-index:251662848;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:middle'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAcI4OuHUCAABiBQAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWykVF1P2zAUfZ+0/2D5HZKmCYWKgFYG
1aRuILr9gFvb+dgcO7PdtOXX79oJNGPSJo0+tLbv8bn3HN/ey+t9I0knjK21yunkNKZEKKZ5rcqc
fvt6d3JOiXWgOEitRE4PwtLrq/fvLmFeGmirmhFkUHYOOa2ca+dRZFklGrCnuhUKY4U2DTjcmjLi
BnbI3MgoieOzqIFa0asj1UdwQLam/g8qqdkPwW9AdWCRUrL5+GSoUbK3M8NcdUvTrtsH4ytnX7oH
Q2qeU3ROQYMW0WgIDDDcRq9ulUeCfWEaj9dFQfY5TeM0zuKMkkNOk3iWTc7jnk/sHWEISKZnSYK5
GAJms+xiNsRZdf8PBlbd/pUDi+yLwcWoQNv68lT3p+L0WfFKFI4sDDBBzl7UP+Ntu8K3sb0LaFd/
Hhw5QtDDze6z5mgfbJ0OTeGLIUa7nJ5kaew/4fhtRr2IhHlrrFsK3RC/yKlEEUFDyALdyjovvOTD
swL/PqGkaCR2egeSnE+naS92DEnGkCwU3SsfCDH/c95gq76rpQwNIxXZ5fQiS7JQgNWy5j7oYdaU
mxtpCObFRgsfnxrJfoMZvVU8kFUC+O2wdlDLfo14qfprQ/u6/To8r9svND/4VBv8xdcIvmOb4Whw
9/hVSI3VMVm3lFTaPL0+8zj8c2GEkh0Ohpzan1swghL5SVnUNUlTpHNhk2Yz38JmHNmMI6AYUmE+
ZyjpNzcO93hp25q6rDDXJNik9Afsl6J2vR199V6HtG7tDlIEO4JGofgDGHhEdRL8eBPqZLkYfEQE
unO0YWvFun0UbODtffJ+e+Cr6RKuDtPQj7Dx/uoXAAAA//8DAFBLAwQUAAYACAAAACEAkn2H4B0H
AABJIAAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1s7FlLbxs3EL4X6H9Y7L2xZL1iI3Jg
yXLcxC9ESoocKYnaZcxdLkjKjm5FcuqlQIG06KEBeuuhKBqgARr00h9jwEGb/ogOuS9SouIHXCAo
bAHG7uw3w+HM7Mzs8M7dZxH1jjEXhMVtv3qr4ns4HrExiYO2/2iw/dlt3xMSxWNEWYzb/gwL/+7G
p5/cQesjSpIhQ3w8CHGEPRAUi3XU9kMpk/WVFTECMhK3WIJjeDZhPEISbnmwMuboBBaI6MpqpdJc
iRCJ/Q2QKJWgHoV/sRSKMKK8r8RgL0YRrH4wmZAR1tjxUVUhxEx0KfeOEW37IHPMTgb4mfQ9ioSE
B22/ov/8lY07K2g9Y6JyCa/Bt63/Mr6MYXy0qtfkwbBYtF5v1JubhXwNoHIR12v1mr1mIU8D0GgE
O011sWW2Vrv1DGuA0kuH7K3WVq1q4Q35tQWdNxvqZ+E1KJVfX8Bvb3fBihZeg1J8YwHf6Kx1tmz5
GpTimwv4VmVzq96y5GtQSEl8tICuNJq1br7bAjJhdMcJX2vUt1urmfASBdFQRJdaYsJiuSzWIvSU
8W0AKCBFksSenCV4gkYQk11EyZATb5cEIQRegmImgFxZrWxXavBf/er6SnsUrWNkcCu9QBOxQFL6
eGLESSLb/n2Q6huQs7dvT5+/OX3+++mLF6fPf83W1qIsvh0UBybf+5+++efVl97fv/34/uW36dLz
eGHi3/3y1bs//vyQeNhxaYqz716/e/P67Puv//r5pUP6JkdDEz4gERbePj7xHrIINujQHw/55TgG
ISImx2YcCBQjtYpDfk+GFnp/hihy4DrYtuNjDqnGBbw3fWop3A/5VBKHxAdhZAH3GKMdxp1WeKDW
Msw8mMaBe3E+NXEPETp2rd1FseXl3jSBHEtcIrshttQ8pCiWKMAxlp56xo4wduzuCSGWXffIiDPB
JtJ7QrwOIk6TDMjQiqaSaYdE4JeZS0Hwt2Wbvcdeh1HXrrfwsY2EdwNRh/IDTC0z3kNTiSKXyAGK
qGnwXSRDl5L9GR+ZuJ6Q4OkAU+b1xlgIF88Bh/0aTn8Aacbt9j06i2wkl+TIJXMXMWYit9hRN0RR
4sL2SRya2M/FEYQo8g6ZdMH3mP2GqHvwA4qXuvsxwZa7z88GjyDDmiqVAaKeTLnDl/cws+K3P6MT
hF2pZpNHVord5MQZHZ1pYIX2LsYUnaAxxt6jzx0adFhi2bxU+n4IWWUHuwLrPrJjVd3HWGBPNzeL
eXKXCCtk+zhgS/TZm80lnhmKI8SXSd4Hr5s270Gpi1wBcEBHRyZwn0C/B/HiNMqBABlGcC+Vehgi
q4Cpe+GO1xm3/HeRdwzey6eWGhd4L4EHX5oHErvJ80HbDBC1FigDZoCgy3ClW2Cx3F+yqOKq2aZO
von90pZugO7IanoiEp/bAc31Po3/rveBDuPsh1eOl+16+h23YCtZXbLTWZZMdub6m2W4+a6my/iY
fPxNzRaaxocY6shixrrpaW56Gv9/39Mse59vOpll/cZNJ+NDh3HTyWTDlevpZMrmBfoaNfBIBz16
7BMtnfpMCKV9OaN4V+jBj4DvmfE2EBWfnm7iYgqYhHCpyhwsYOECjjSPx5n8gsiwH6IEpkNVXwkJ
RCY6EF7CBAyNNNkpW+HpNNpj43TYWa2qwWZaWQWSJb3SKOgwqJIputkqB3iFeK1toAetuQKK9zJK
GIvZStQcSrRyojKSHuuC0RxK6J1dixZrDi1uK/G5qxa0ANUKr8AHtwef6W2/UQcWYIJ5HDTnY+Wn
1NW5d7Uzr9PTy4xpRQA02HkElJ5eU7ou3Z7aXRpqF/C0pYQRbrYS2jK6wRMhfAZn0amoF1Hjsr5e
K11qqadModeD0CrVaN3+kBZX9TXwzecGGpuZgsbeSdtv1hoQMiOUtP0JDI3hMkogdoT65kI0gOOW
keTpC3+VzJJwIbeQCFOD66STZoOISMw9SqK2r7ZfuIHGOodo3aqrkBA+WuXWIK18bMqB020n48kE
j6TpdoOiLJ3eQoZPc4XzqWa/Olhxsim4ux+OT7whnfKHCEKs0aoqA46JgLODamrNMYHDsCKRlfE3
V5iytGueRukYSumIJiHKKoqZzFO4TuWFOvqusIFxl+0ZDGqYJCuEw0AVWNOoVjUtqkaqw9Kqez6T
spyRNMuaaWUVVTXdWcxaIS8Dc7a8WpE3tMpNDDnNrPBp6p5PuWt5rpvrE4oqAQYv7OeouhcoCIZq
5WKWakrjxTSscnZGtWtHvsFzVLtIkTCyfjMXO2e3okY4lwPilSo/8M1HLZAmeV+pLe062N5DiTcM
qm0fDpdhOPgMruB42gfaqqKtKhpcwZkzlIv0oLjtZxc5BZ6nlAJTyym1HFPPKfWc0sgpjZzSzClN
39MnqnCKrw5TfS8/MIUalh2wZr2Fffq/8S8AAAD//wMAUEsDBBQABgAIAAAAIQCcZkZBuwAAACQB
AAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzhI/NCsIwEITv
gu8Q9m7SehCRJr2I0KvUBwjJNi02PyRR7Nsb6EVB8LIws+w3s037sjN5YkyTdxxqWgFBp7yenOFw
6y+7I5CUpdNy9g45LJigFdtNc8VZ5nKUxikkUigucRhzDifGkhrRykR9QFc2g49W5iKjYUGquzTI
9lV1YPGTAeKLSTrNIXa6BtIvoST/Z/thmBSevXpYdPlHBMulFxagjAYzB0pXZ501LV2BiYZ9/Sbe
AAAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAAAAAAAAAAAAAAAAAAABbQ29u
dGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAAAAAAAAAAAAAA
NgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAHCODrh1AgAAYgUAAB8AAAAAAAAAAAAAAAAA
IAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWxQSwECLQAUAAYACAAAACEAkn2H4B0H
AABJIAAAGgAAAAAAAAAAAAAAAADSBAAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWxQSwECLQAU
AAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAAAAAAAAAAAAAAAnDAAAY2xpcGJvYXJkL2RyYXdpbmdz
L19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAAAAAFAAUAZwEAACoNAAAAAA==
" adj="548"/><![endif]--></p><p>Administration of dostarlimab should continue according to the recommended schedule until disease progression or unacceptable toxicity (see section 5.1).</p><p><em>Dose modifications </em></p><p>Dose reduction is not recommended. Dosing delay or discontinuation may be required based on individual safety and tolerability. Recommended modifications to manage adverse reactions are provided in Table&nbsp;3.</p><p>Detailed guidelines for the management of immune‑related adverse reactions and infusion‑related reactions are described in section&nbsp;4.4.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;3. Recommended dose modifications for JEMPERLI</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune‑related adverse reactions </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Severity grade<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Dose modification</strong></p></td></tr></thead><tbody><tr><td rowspan="2"><p>Colitis</p></td><td><p>2 or 3</p><p>&nbsp;</p></td><td><p>Withhold dose. Restart dosing when toxicity resolves to grade&nbsp;0 or 1.</p></td></tr><tr><td><p>4</p></td><td><p>Permanently discontinue.</p></td></tr><tr><td rowspan="2"><p>Hepatitis</p></td><td><p>Grade&nbsp;2 with AST<sup>b</sup> or ALT<sup>c</sup> &gt;&nbsp;3 and</p><p>up to 5&nbsp;&times;&nbsp;ULN<sup>d</sup></p><p>or</p><p>total bilirubin &gt;&nbsp;1.5 and up to 3&nbsp;&times;&nbsp;ULN</p></td><td><p>Withhold dose. Restart dosing when toxicity resolves to grade&nbsp;0 or 1.</p></td></tr><tr><td><p>Grade&nbsp;&ge;&nbsp;3 with AST or ALT &gt;&nbsp;5&nbsp;&times;&nbsp;ULN</p><p>or</p><p>&nbsp;total bilirubin &gt;&nbsp;3&nbsp;&times;&nbsp;ULN</p></td><td><p>Permanently discontinue (see exception below)<sup>e</sup>.</p></td></tr><tr><td><p>Type&nbsp;1 diabetes mellitus (T1DM)</p></td><td><p>3 or 4 (hyperglycaemia)</p></td><td><p><br />Withhold dose. Restart dosing in appropriately managed, clinically and metabolically stable patients.</p><p>&nbsp;</p></td></tr><tr><td><p>Hypophysitis or adrenal insufficiency</p></td><td><p>2, 3 or 4</p><p>&nbsp;</p></td><td><p>Withhold dose. Restart dosing when toxicity resolves to grade&nbsp;0 or 1. Permanently discontinue for recurrence or worsening while on adequate hormonal therapy.</p></td></tr><tr><td><p>Hypothyroidism or hyperthyroidism</p></td><td><p>&nbsp;</p><p>3 or 4</p></td><td><p>Withhold dose. Restart dosing when toxicity resolves to grade&nbsp;0 or 1.</p></td></tr><tr><td rowspan="2"><p>Pneumonitis</p></td><td><p>2</p></td><td><p>Withhold dose. Restart dosing when toxicity resolves to grade&nbsp;0 or 1. If grade&nbsp;2 recurs, permanently discontinue.</p></td></tr><tr><td><p>3 or 4</p></td><td><p>Permanently discontinue.</p></td></tr><tr><td rowspan="2"><p>Nephritis</p></td><td><p>2</p></td><td><p>Withhold dose. Restart dosing when toxicity resolves to grade&nbsp;0 or 1.</p></td></tr><tr><td><p>3 or 4</p></td><td><p>Permanently discontinue.</p></td></tr><tr><td rowspan="2"><p>Exfoliative dermatologic conditions (e.g. SJS, TEN, DRESS)</p></td><td><p>Suspected</p></td><td><p>Withhold dose for any grade. Restart dosing if not confirmed and when toxicity resolves to grade&nbsp;0 or 1.</p></td></tr><tr><td><p>Confirmed</p></td><td><p>Permanently discontinue.</p></td></tr><tr><td><p>Myocarditis</p></td><td><p>2, 3 or 4</p></td><td><p>Permanently discontinue.</p></td></tr><tr><td><p>Severe neurological toxicities (myasthenic syndrome/myasthenia gravis, Guillain-Barr&eacute; syndrome, encephalitis, transverse myelitis)</p></td><td><p>2, 3 or 4</p></td><td><p>Permanently discontinue.</p></td></tr><tr><td rowspan="2"><p>Other immune‑related adverse reactions (including but not limited to myositis, sarcoidosis, autoimmune haemolytic anaemia, pancreatitis, iridocyclitis, uveitis, diabetic ketoacidosis, arthralgia, solid organ transplant rejection, graft-versus-host disease)</p></td><td><p>3</p></td><td><p>Withhold dose. Restart dosing when toxicity resolves to grade&nbsp;0 or 1.</p></td></tr><tr><td><p>4</p></td><td><p>Permanently discontinue.</p></td></tr><tr><td><p>&nbsp;</p><p>Recurrence of immune‑related adverse reactions after resolution to &le;&nbsp;grade&nbsp;1 (except for pneumonitis, see above)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>3 or 4</p></td><td><p>Permanently discontinue.</p></td></tr><tr><td><p><strong>Other adverse reactions</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Severity grade<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Dose modification</strong></p></td></tr><tr><td rowspan="2"><p>Infusion‑related reactions</p><p>&nbsp;</p></td><td><p>2</p></td><td><p>Withhold dose. If resolved within 1 hour of stopping, may be restarted at 50&nbsp;% of the original infusion rate, or restart when symptoms resolve with pre‑medication. If grade&nbsp;2 recurs with adequate premedication, permanently discontinue.</p></td></tr><tr><td><p>3 or 4</p></td><td><p>Permanently discontinue.</p></td></tr></tbody></table><p><sup>a </sup>Toxicity graded per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version&nbsp;5.0.</p><p><sup>b </sup>AST = aspartate aminotransferase</p><p><sup>c</sup> ALT = alanine aminotransferase</p><p><sup>d</sup> ULN = upper limit of normal</p><p><sup>e </sup>For patients with liver metastases who begin treatment with grade&nbsp;2 increase of AST or ALT, if AST or ALT increases by &ge;&nbsp;50&nbsp;% relative to baseline and lasts for at least 1&nbsp;week, then treatment should be discontinued.</p><p><u>Patient Card</u></p><p>All prescribers of JEMPERLI should inform patients about the Patient Card, explaining what to do should they experience any symptom of immune‑related adverse reactions. The physician will provide the Patient Card to each patient.</p><p><em><u>Special populations</u></em></p><p><em>Elderly</em></p><p>No dose adjustment is recommended for patients who are aged 65&nbsp;years or over.</p><p>There are limited clinical data with dostarlimab in patients aged 75&nbsp;years or over (see section 5.1).</p><p><em>Renal impairment</em></p><p>No dose adjustment is recommended for patients with mild or moderate renal impairment. There are limited data in patients with severe renal impairment or end‑stage renal disease undergoing dialysis (see section&nbsp;5.2).</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is recommended for patients with mild hepatic impairment. There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment (see section&nbsp;5.2).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of JEMPERLI in children and adolescents aged under 18&nbsp;years have not been established. No data are available.</p><p><u>Method of administration</u></p><p>JEMPERLI is for intravenous infusion only. JEMPERLI should be administered by intravenous infusion using an intravenous infusion pump over 30&nbsp;minutes.</p><p>JEMPERLI must not be administered as an intravenous push or bolus injection.</p><p>For instructions on dilution of the medicinal product before administration, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the tradename and the batch number of the administered product should be clearly recorded.</p><p><u>Immune‑related adverse reactions</u></p><p>Immune‑related adverse reactions, which may be severe or fatal, can occur in patients treated with antibodies blocking the programmed cell death protein‑1 / programmed death‑ligand&nbsp;1 (PD‑1/PD‑L1) pathway, including dostarlimab. While immune‑related adverse reactions usually occur during treatment with PD‑1/PD‑L1 blocking antibodies, symptoms can also manifest after discontinuation of treatment. Immune‑related adverse reactions may occur in any organ or tissue and may affect more than one body system simultaneously. Important immune‑related adverse reactions listed in this section are not inclusive of all possible severe and fatal immune‑related reactions.</p><p>Early identification and management of immune‑related adverse reactions are essential to ensure safe use of PD‑1/PD‑L1 blocking antibodies. Patients should be monitored for symptoms and signs of immune‑related adverse reactions. Haematological and clinical chemistries, including liver, kidney and thyroid function tests, should be evaluated at baseline and periodically during treatment. For suspected immune‑related adverse reactions, adequate evaluation including specialty consultation should be ensured.</p><p>Based on the severity of the adverse reaction, treatment with dostarlimab should be withheld or permanently discontinued and corticosteroids (1 to 2&nbsp;mg/kg/day prednisone or equivalent) or other appropriate therapy administered (see below and section&nbsp;4.2)<em>.</em> Upon improvement to Grade&nbsp;&le;1, corticosteroid taper should be initiated and continued for 1&nbsp;month or longer. Based on limited data from clinical studies in patients whose immune‑related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered. Hormone replacement therapy for endocrinopathies should be instituted as warranted.</p><p>Treatment with dostarlimab should be permanently discontinued for any Grade&nbsp;3 immune‑related adverse reaction that recurs and for any Grade&nbsp;4 immune‑related adverse reaction toxicity, except for endocrinopathies that are controlled with replacement hormones and unless otherwise specified in Table&nbsp;3.</p><p><em><u>Immune‑related pneumonitis</u></em></p><p>Pneumonitis has been reported in patients receiving dostarlimab (see section&nbsp;4.8). Patients should be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other causes excluded. Patients should be managed with dostarlimab treatment modifications and corticosteroids (see section&nbsp;4.2).</p><p><em><u>Immune‑related colitis</u></em></p><p>Dostarlimab can cause immune‑related colitis (see section&nbsp;4.8). Patients should be monitored for signs and symptoms of colitis and managed with dostarlimab treatment modifications, anti‑diarrhoeal agents and corticosteroids (see section&nbsp;4.2).</p><p><em><u>Immune‑related hepatitis</u></em></p><p>Dostarlimab can cause immune‑related hepatitis (see section&nbsp;4.8). Patients should be monitored for changes in liver function periodically as indicated, based on clinical evaluation and managed with dostarlimab treatment modifications and corticosteroids (see section&nbsp;4.2).</p><p><em><u>Immune‑related endocrinopathies</u></em></p><p>Immune‑related endocrinopathies, including hypothyroidism, hyperthyroidism, thyroiditis, hypophysitis, type 1 diabetes mellitus, diabetic ketoacidosis and adrenal insufficiency, have been reported in patients receiving dostarlimab (see section&nbsp;4.8).</p><p><em>Hypothyroidism and hyperthyroidism</em></p><p>Immune‑related hypothyroidism and hyperthyroidism (including thyroiditis) occurred in patients receiving dostarlimab, and hypothyroidism may follow hyperthyroidism. Patients should be monitored for abnormal thyroid function tests prior to and periodically during treatment and as indicated based on clinical evaluation. Immune‑related hypothyroidism and hyperthyroidism (including thyroiditis) should be managed as recommended in section&nbsp;4.2.</p><p><em>Adrenal insufficiency</em></p><p>Immune‑related adrenal insufficiency occurred in patients receiving dostarlimab. Patients should be monitored for clinical signs and symptoms of adrenal insufficiency. For symptomatic adrenal insufficiency, patients should be managed as recommended in section&nbsp;4.2.</p><p><em><u>Immune‑related nephritis</u></em></p><p>Dostarlimab can cause immune‑related nephritis (see section&nbsp;4.8). Patients should be monitored for changes in renal function and manage with dostarlimab treatment modifications and corticosteroids (see section&nbsp;4.2).</p><p><em><u>Immune‑related rash</u></em></p><p>Immune-related rash has been reported in patients receiving dostarlimab, including pemphigoid (see section&nbsp;4.8). Patients should be monitored for signs and symptoms of rash. Exfoliative dermatologic conditions should be managed as recommended in section&nbsp;4.2. Events of Stevens-Johnson Syndrome or toxic epidermal necrolysis have been reported in patients treated with PD‑1 inhibitors.</p><p>Caution should be used when considering the use of dostarlimab in a patient who has previously experienced a severe or life‑threatening skin adverse reaction on prior treatment with other immune‑stimulatory anticancer agents.</p><p><em><u>Immune‑related arthralgia</u></em></p><p>Immune‑related arthralgia has been reported in patients receiving dostarlimab (see section&nbsp;4.8). Patients should be monitored for signs and symptoms of arthralgia. Suspected immune‑related arthralgia should be confirmed and other causes excluded. Patients should be managed with dostarlimab treatment modifications and corticosteroids (see section&nbsp;4.2).</p><p><em><u>Other immune‑related adverse reactions</u></em></p><p>Given the mechanism of action of dostarlimab other potential immune‑related adverse reactions may occur, including potentially serious events [e.g. myositis, myocarditis, encephalitis, demyelinating neuropathy (including Guillain Barr&eacute; syndrome), sarcoidosis]. Clinically significant immune‑related adverse reactions reported in less than 1&nbsp;% of patients treated with dostarlimab as monotherapy in clinical studies include encephalitis, autoimmune haemolytic anaemia, pancreatitis, iridocyclitis and uveitis. Patients should be monitored for signs and symptoms of immune‑related adverse reactions and managed as described in section&nbsp;4.2. Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-1 inhibitors. Treatment with dostarlimab may increase the risk of rejection in solid organ transplant recipients. The benefit of treatment with dostarlimab versus the risk of possible organ rejection should be considered in these patients.</p><p>Fatal and other serious complications can occur in patients who receive allogeneic haematopoietic stem cell transplantation (HSCT) before or after being treated with a PD‑1/PD-L1&ndash;blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GvHD), acute GvHD, chronic GvHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1&ndash;blocking antibody prior to or after an allogeneic HSCT.</p><p><em><u>Infusion‑related reactions</u></em></p><p>Dostarlimab can cause infusion‑related reactions, which can be severe (see section&nbsp;4.8). For severe (grade&nbsp;3) or life‑threatening (grade&nbsp;4) infusion‑related reactions, the infusion should be stopped and treatment should be permanently discontinued (see section&nbsp;4.2).<!--[if supportFields]><span
lang=EN-US style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US;mso-no-proof:
yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6c0f421a-153c-4c0d-bdc6-1cdb0c1999e4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-US style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US;mso-no-proof:
yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p><em><u>Patients excluded from clinical studies</u></em><!--[if supportFields]><span
style='mso-element:field-begin'></span>DOCVARIABLE
vault_nd_8ee4f024-9635-459c-80be-77a509c34aa4 \* MERGEFORMAT<span
style='mso-element:field-separator'></span><![endif]--><em><u> </u></em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><u><span lang=EN-US style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-US;mso-bidi-font-weight:bold;mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></u></i><![endif]--></p><p>Patients with the following status were excluded from the GARNET study: Eastern Cooperative Oncology Group (ECOG) baseline performance score (PS) &ge;&nbsp;2; uncontrolled central nervous system metastases or carcinomatous meningitis; other malignancies within the last 2&nbsp;years; immunodeficiency or receiving immunosuppressive therapy within 7&nbsp;days; active HIV, hepatitis B or hepatitis C infection; active autoimmune disease requiring systemic treatment in the past 2&nbsp;years excluding replacement therapy; history of interstitial lung disease; or receiving live vaccine within 14&nbsp;days.<!--[if supportFields]><span
lang=EN-US style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US;mso-bidi-font-weight:
bold;mso-bidi-font-style:italic;mso-no-proof:yes'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_3dc43dd5-6fa0-4a0c-8f86-b72427fc7f42
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-US style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US;mso-bidi-font-weight:
bold;mso-bidi-font-style:italic;mso-no-proof:yes'><span style='mso-element:
field-end'></span></span><![endif]-->&nbsp;</p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per 500 mg dose, i.e. essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. Monoclonal antibodies (mAb) such as dostarlimab are not substrates for cytochrome P450 or active substance transporters. Dostarlimab is not a cytokine and is unlikely to be a cytokine modulator. Additionally,<sup> </sup>pharmacokinetic<sup> </sup>(PK) interaction of dostarlimab with small molecule active substances is not expected. There is no evidence of interaction mediated by non‑specific clearance of lysosome degradation for antibodies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception</u></p><p>There is a risk associated with the administration of dostarlimab to women of childbearing potential. Women of childbearing potential must use effective contraception during treatment with dostarlimab and until 4&nbsp;months after the last dose of dostarlimab.</p><p><u>Pregnancy</u></p><p>There are no or limited amount of data on the use of dostarlimab in pregnant women. Based on its mechanism of action, dostarlimab can cause foetal harmful pharmacological effects when administered during pregnancy<em>.</em></p><p>Animal reproduction and development studies have not been conducted with dostarlimab; however, inhibition of the PD‑1/PD‑L1 pathway can lead to increased risk of immune‑mediated rejection of the developing foetus resulting in foetal death (see section&nbsp;5.3)<em>.</em> Human immunoglobulins (IgG4) are known to cross the placental barrier, and therefore, being an IgG4, dostarlimab has the potential to be transmitted from the mother to the developing foetus.</p><p>JEMPERLI is not recommended during pregnancy and in women of childbearing potential not using effective contraception.</p><p><u>Breast‑feeding</u></p><p>It is unknown whether dostarlimab/metabolites are excreted in human milk.</p><p>A risk to the newborns/infants cannot be excluded.</p><p>JEMPERLI should not be used during breast‑feeding and breast‑feeding should be avoided for at least 4&nbsp;months after the last dose of dostarlimab.</p><p><u>Fertility</u></p><p>Fertility studies have not been conducted with dostarlimab (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>JEMPERLI has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Dostarlimab is most commonly associated with immune-related adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of dostarlimab (see &ldquo;Description of selected adverse reactions&rdquo; below).</p><p><em><u>Dostarlimab in monotherapy</u></em></p><p>The safety of dostarlimab has been evaluated in 605&nbsp;patients with EC or other advanced solid tumours who received dostarlimab monotherapy in the GARNET study, including 153&nbsp;patients with advanced or recurrent dMMR/MSI-H EC. Patients received doses of 500&nbsp;mg every 3&nbsp;weeks for 4&nbsp;cycles followed by 1000&nbsp;mg every 6&nbsp;weeks for all cycles thereafter.</p><p>In patients with advanced or recurrent solid tumours (N&nbsp;=&nbsp;605), the most common adverse reactions (&gt;&nbsp;10 %) were anaemia (28.6&nbsp;%), diarrhoea (26.0&nbsp;%), nausea (25.8&nbsp;%), vomiting (19.0&nbsp;%), arthralgia (17.0&nbsp;%), pruritus (14.2&nbsp;%), rash (13.2&nbsp;%), pyrexia (12.4&nbsp;%), aspartate aminotransferase increased (11.2 %) and hypothyroidism (11.2&nbsp;%). JEMPERLI was permanently discontinued due to adverse reactions in 38 (6.3&nbsp;%) patients; most of them were immune‑related events. Adverse reactions were serious in 11.2&nbsp;% of patients; most serious adverse reactions were immune-related adverse reactions (see section&nbsp;4.4).</p><p>The safety profile for patients with dMMR/MSI-H EC in the GARNET study (N=153) was not different from that of the overall monotherapy population presented in Table 4.</p><p><em>Dostarlimab in combination with </em><em>carboplatin and paclitaxel</em></p><p>The safety of dostarlimab has been evaluated in 241&nbsp;patients with primary advanced or recurrent EC who received dostarlimab in combination with carboplatin and paclitaxel in the RUBY study. Patients received doses of 500&nbsp;mg dostarlimab every 3&nbsp;weeks for 6&nbsp;cycles followed by 1000&nbsp;mg every 6&nbsp;weeks for all cycles thereafter.</p><p>In patients with primary advanced or recurrent EC (N = 241), the most common adverse reactions (&gt;&nbsp;10 %) were rash (22.8 %), rash maculopapular (14.1%), hypothyroidism (14.1 %), alanine aminotransferase increased (12.9 %), aspartate aminotransferase increased (12.0 %), pyrexia (12.0 %) and dry skin (10.4 %). JEMPERLI was permanently discontinued due to adverse reactions in 12 (5.0&nbsp;%) patients; most were immune‑related events. Adverse reactions were serious in 5.8&nbsp;% of patients; most serious adverse reactions were immune-related adverse reactions (see section&nbsp;4.4).</p><p>In the RUBY study the safety profile for patients with dMMR/MSI-H EC (N=52) was not different from that of the overall population (N=241) presented in Table 4.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions reported in clinical trials of dostarlimab as a monotherapy or in combination with chemotherapy are listed in Table 4 by system organ class and by frequency. The frequencies of adverse reactions listed in the dostarlimab monotherapy column are based on all-cause adverse event frequency identified in 605 patients with advanced or recurrent solid tumours from the GARNET study exposed to dostarlimab monotherapy for a median duration of treatment of 24&nbsp;weeks (range: 1&nbsp;week to 229&nbsp;weeks). Unless otherwise stated, the frequencies of adverse reactions listed in the dostarlimab in combination with chemotherapy column are based on all-cause adverse event frequency identified in 241 patients with primary advanced or recurrent EC from the RUBY study exposed to dostarlimab in combination with carboplatin and paclitaxel for a median duration of treatment of 43&nbsp;weeks (range: 3 to 151&nbsp;weeks). For additional safety information when dostarlimab is administered in combination with carboplatin and paclitaxel, refer to the respective Prescribing Information for the combination products.</p><p>Adverse reactions known to occur with dostarlimab as monotherapy, or with carboplatin or paclitaxel given alone, may occur during treatment with these medicinal products in combination, even if these reactions were not reported in clinical studies with dostarlimab in combination with carboplatin and paclitaxel. These reactions are presented by system organ class and by frequency. Frequencies are defined as: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to&nbsp;&lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000); and not known (cannot be estimated from the available data).</p><p><strong>Table&nbsp;</strong><strong>4: Adverse reactions in patients treated with dostarlimab</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:93%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Dostarlimab monotherapy</strong></p></td><td style="vertical-align:top"><p><strong>Dostarlimab in combination with chemotherapy</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anaemia<sup>a</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypothyroidism*<sup>b</sup></p></td><td style="vertical-align:top"><p>Hypothyroidism<sup>e</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperthyroidism*, adrenal insufficiency*</p></td><td style="vertical-align:top"><p>Hyperthyroidism, adrenal insufficiency</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thyroiditis*<sup>c</sup>, hypophysitis<sup>d</sup></p></td><td style="vertical-align:top"><p>Thyroiditis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Type 1 diabetes mellitus, diabetic ketoacidosis</p></td><td style="vertical-align:top"><p>Type 1 diabetes mellitus</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Encephalitis, myasthenia gravis</p></td><td style="vertical-align:top"><p>Myasthenic syndrome<sup>f</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uveitis<sup>g</sup></p></td><td style="vertical-align:top"><p>Uveitis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocarditis<sup>h</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pneumonitis*<sup>i</sup></p></td><td style="vertical-align:top"><p>Pneumonitis</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea, nausea,</p><p>vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Colitis*<sup>j</sup>, pancreatitis<sup>k</sup>, gastritis</p></td><td style="vertical-align:top"><p>Colitis<sup>l</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Oesophagitis</p></td><td style="vertical-align:top"><p>Pancreatitis,</p><p>immune mediated gastritis<sup>f</sup>, vasculitis gastrointestinal<sup>f</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hepatitis*<sup>m</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Rash*<sup>n</sup>, pruritus</p></td><td style="vertical-align:top"><p>Rash<sup>o</sup>, dry skin</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Arthralgia*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Immune-mediated arthritis, polymyalgia rheumatica, immune-mediated myositis</p></td><td style="vertical-align:top"><p>Immune-mediated arthritis, myositis<sup>p</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nephritis*<sup>q</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Systemic inflammatory response syndrome<sup>p</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Transaminases increased<sup>r</sup></p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased,</p><p>aspartate aminotransferase increased</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Infusion-related reaction*<sup>s</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>* </sup>See section &lsquo;Description of selected adverse reactions.&rsquo;</p><p><sup>a</sup> Includes anaemia and autoimmune haemolytic anaemia</p><p><sup>b</sup> Includes hypothyroidism and autoimmune hypothyroidism</p><p><sup>c</sup> Includes thyroiditis and autoimmune thyroiditis</p><p><sup>d</sup> Includes hypophysitis and lymphocytic hypophysitis</p><p><sup>e</sup> Includes hypothyroidism and immune-mediated hypothyroidism</p><p><sup>f</sup> Reported from ongoing blinded trial of dostarlimab in combination; estimated frequency category</p><p><sup>g</sup> Includes uveitis and iridocyclitis</p><p><sup>h</sup> Includes myocarditis (combination with chemotherapy) and immune-mediated myocarditis from ongoing blinded trial of dostarlimab in combination; estimated frequency category</p><p><sup>i</sup> Includes pneumonitis, interstitial lung disease and immune-mediated lung disease</p><p><sup>j</sup> Includes colitis, enterocolitis and immune-mediated enterocolitis</p><p><sup>k </sup>Includes pancreatitis and pancreatitis acute</p><p><sup>l </sup>Includes colitis (combination with chemotherapy) and enteritis reported from ongoing trial of dostarlimab in combination</p><p><sup>m</sup> Includes hepatitis, autoimmune hepatitis and hepatic cytolysis</p><p><sup>n</sup> Includes rash, rash maculo-papular, erythema, rash macular, rash pruritic, rash erythematous, rash papular, erythema multiforme, skin toxicity, drug eruption, toxic skin eruption, exfoliative rash and pemphigoid</p><p><sup>o </sup>Includes rash and rash maculo-papular</p><p><sup>p</sup> Reported in ongoing trial of dostarlimab in combination</p><p><sup>q </sup>Includes nephritis and tubulointerstitial nephritis</p><p><sup>r</sup> Includes transaminases increased, alanine aminotransferases increased, aspartate aminotransferases increased and hypertransaminasaemia</p><p><sup>s </sup>Includes infusion-related reaction and hypersensitivity.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>The selected adverse reactions described below are based on the safety of dostarlimab in a combined monotherapy safety database of 605&nbsp;patients in the GARNET study in patients with EC or other advanced solid tumours. Immune‑related adverse reactions were defined as events of grade&nbsp;2 and above; the frequencies below exclude grade&nbsp;1 events. The management guidelines for these adverse reactions are described in section&nbsp;4.2.</p><p><em><u>Immune‑related adverse reactions (see section&nbsp;4.4)</u></em></p><p><em>Immune‑related pneumonitis</em></p><p>Immune‑related pneumonitis occurred in 14 (2.3&nbsp;%) patients, including grade&nbsp;2 (1.3&nbsp;%), grade&nbsp;3 (0.8&nbsp;%) and grade 4 (0.2 %) pneumonitis. Pneumonitis led to discontinuation of dostarlimab in 8 (1.3&nbsp;%) patients.</p><p>Systemic corticosteroids (prednisone &ge;&nbsp;40&nbsp;mg per day or equivalent) were required in 11 (78.6&nbsp;%)&nbsp;patients experiencing pneumonitis. Pneumonitis resolved in 11 (78.6&nbsp;%) patients.</p><p><em>Immune‑related colitis</em></p><p>Colitis occurred in 8 (1.3&nbsp;%) patients, including grade&nbsp;2 (0.7&nbsp;%) and grade&nbsp;3 (0.7&nbsp;%) colitis. Colitis did not lead to discontinuation of dostarlimab in any patients.</p><p>Systemic corticosteroids (prednisone &ge;&nbsp;40&nbsp;mg per day or equivalent) were required in 5 (62.5&nbsp;%) patients. Colitis resolved in 5 (62.5&nbsp;%) patients experiencing colitis.</p><p><em>Immune‑related hepatitis</em></p><p>Hepatitis occurred in 3 (0.5&nbsp;%) patients, all of which were grade&nbsp;3. Systemic corticosteroids (prednisone &ge;&nbsp;40&nbsp;mg per day or equivalent) were required in 2 (66.7&nbsp;%) patients. Hepatitis led to discontinuation of dostarlimab in 1 (0.2%) patient and resolved in 2 of the 3 patients.</p><p><em>Immune‑mediated endocrinopathies</em></p><p>Hypothyroidism occurred in 46 (7.6&nbsp;%) patients, all of which were grade&nbsp;2. Hypothyroidism did not lead to discontinuation of dostarlimab and resolved in 17 (37.0&nbsp;%) patients.</p><p>Hyperthyroidism occurred in 14 (2.3&nbsp;%) patients, including grade&nbsp;2 (2.1&nbsp;%) and grade&nbsp;3 (0.2&nbsp;%). Hyperthyroidism did not lead to discontinuation of dostarlimab and resolved in 10 (71.4&nbsp;%) patients.</p><p>Thyroiditis occurred in 3 (0.5&nbsp;%) patients; all were grade&nbsp;2. None of the events of thyroiditis resolved; there were no discontinuations of dostarlimab due to thyroiditis.</p><p>Adrenal insufficiency occurred in 7 (1.2&nbsp;%) patients, including grade&nbsp;2 (0.5&nbsp;%), and grade&nbsp;3 (0.7&nbsp;%). Adrenal insufficiency resulted in discontinuation of dostarlimab in 1 (0.2&nbsp;%) patient and resolved in 4 (57.1&nbsp;%) patients.</p><p><em>Immune‑mediated nephritis </em></p><p>Nephritis, including tubulointerstitial nephritis, occurred in 3 (0.5&nbsp;%) patients; all were grade&nbsp;2. Systemic corticosteroids (prednisone &ge;&nbsp;40&nbsp;mg per day or equivalent) were required in 2 (66.7&nbsp;%) patients experiencing nephritis. Nephritis led to discontinuation of dostarlimab in 1 (0.2&nbsp;%) patient and resolved in all 3 patients.</p><p><em>Immune‑related rash</em></p><p>Immune-related rash (rash, rash maculo-papular, rash macular, rash pruritic, pemphigoid, drug eruption, skin toxicity, toxic skin eruption) occurred in 31 (5.1&nbsp;%) patients, including Grade&nbsp;3 in 9 (1.5&nbsp;%) patients receiving dostarlimab. The median time to onset of rash was 57 days (range 2&nbsp;days to 1485&nbsp;days). Systemic corticosteroids (prednisone &ge;&nbsp;40&nbsp;mg per day or equivalent) were required in 9 (29.0&nbsp;%) patients experiencing rash. Rash led to discontinuation of dostarlimab in 1 (0.2&nbsp;%) patient and resolved in 24 (77.4&nbsp;%) patients.</p><p><em>Immune‑related arthralgia</em></p><p>Immune‑related arthralgia occurred in 34 (5.6&nbsp;%) patients. Grade&nbsp;3 immune‑related arthralgia was reported in 5 (0.8&nbsp;%) patients receiving dostarlimab. The median time to onset of arthralgia was 94.5&nbsp;days (range 1&nbsp;day to 840&nbsp;days). Systemic corticosteroids (prednisone &ge;&nbsp;40&nbsp;mg per day or equivalent) were required in 3&nbsp;(8.8&nbsp;%) patients experiencing arthralgia. Arthralgia led to discontinuation of dostarlimab in 1 (0.2&nbsp;%) patient and resolved in 19 (55.9&nbsp;%) patients experiencing arthralgia.</p><p><em>Infusion‑related reactions </em></p><p>Infusion‑related reactions including hypersensitivity occurred in 6 (1.0&nbsp;%) patients, including grade&nbsp;2 (0.3&nbsp;%) and grade&nbsp;3 (0.2&nbsp;%) infusion‑related reactions. All patients recovered from the infusion‑related reaction.</p><p><u>Immunogenicity</u></p><p>In the GARNET study, anti‑drug antibodies (ADA) were tested in 315&nbsp;patients who received dostarlimab and the incidence of dostarlimab treatment‑emergent ADAs was 2.5&nbsp;%. Neutralising antibodies were detected in 1.3&nbsp;% of patients. Co-administration with carboplatin and paclitaxel did not affect dostarlimab immunogenicity. In the RUBY study, of the 225 patients who were treated with dostarlimab in combination with carboplatin and paclitaxel and evaluable for the presence of ADAs, there was no incidence of dostarlimab treatment-emergent ADA or treatment‑emergent neutralising antibodies.</p><p>In the patients who developed ADAs, there was no evidence of altered efficacy or safety of dostarlimab.</p><p><u>Elderly population</u></p><p>Of the 605&nbsp;patients treated with dostarlimab monotherapy, 51.6&nbsp;% were under 65&nbsp;years, 36.9&nbsp;% were 65 to less than 75&nbsp;years, and 11.5&nbsp;% were 75&nbsp;years or older. No overall differences in safety were reported between elderly (&ge;&nbsp;65&nbsp;years) and younger patients (&lt;&nbsp;65&nbsp;years).</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>SFDA Call Centre: 19999</li><li>E-mail: <u>npc.drug@sfda.gov.sa</u>&nbsp;</li><li>Website: <u>https://ade.sfda.gov.sa</u></li></ul><p><strong>-GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: <u>s</u><u>audi.safety@gsk.com</u><u>&nbsp; </u></li><li>Website: <u>https://gskpro.com/en-sa/</u><u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: <u>gcc.medinfo@gsk.com</u></li><li>Website: <u>https://gskpro.com/en-sa/</u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If overdose is suspected, the patient should be monitored for any signs or symptoms of adverse reactions or effects, and appropriate symptomatic treatment instituted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti‑neoplastic agents, monoclonal antibodies and antibody drug conjugates, ATC code: L01FF07<!--[if supportFields]><span
style='mso-element:field-begin'></span>DOCVARIABLE
vault_nd_b9566e91-bb35-4369-a960-193a3ba3944a \* MERGEFORMAT<span
style='mso-element:field-separator'></span><![endif]--> <!--[if supportFields]><span style='mso-bidi-font-size:
11.0pt;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p><u>Mechanism of action</u></p><p>Dostarlimab is a humanised mAb of the IgG4 isotype that binds to PD‑1 receptors and blocks the interactions of binding with its ligands PD‑L1 and PD‑L2. The inhibition of PD‑1 pathway‑mediated immune response results in inhibition of T‑cell function such as proliferation, cytokine production, and cytotoxic activity. Dostarlimab potentiates T-cell responses, including anti‑tumour immuno responses through blockade of PD‑1 binding to PD‑L1 and PD‑L2. In syngeneic mouse tumour models, blocking PD‑1 activity resulted in decreased tumour growth.</p><p><u>Clinical efficacy and safety</u></p><p><em>RUBY: Randomised controlled study of dostarlimab in combination with carboplatin and paclitaxel in treatment of adult patients with primary advanced or recurrent EC </em></p><p>The efficacy and safety of dostarlimab in combination with carboplatin-paclitaxel were investigated in a multicentre, randomised, double blinded, placebo-controlled Phase 3 study conducted in patients with primary advanced or recurrent EC.</p><p>Patients were randomised (1:1) to receive dostarlimab 500&nbsp;mg plus carboplatin AUC 5&nbsp;mg/mL/min and paclitaxel 175&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks for 6&nbsp;cycles followed by dostarlimab 1000&nbsp;mg every 6&nbsp;weeks (n&nbsp;=&nbsp;245) or placebo plus carboplatin AUC 5&nbsp;mg/mL/min and paclitaxel 175&nbsp;mg/m<sup>2</sup> every 3&nbsp;weeks for 6&nbsp;cycles followed by placebo every 6&nbsp;weeks (n&nbsp;=&nbsp;249). Randomisation was stratified by MMR/MSI status, prior external pelvic radiotherapy, and disease status (recurrent, primary Stage III, or primary Stage IV). Treatment continued for up to 3 years or until unacceptable toxicity, disease progression or investigator decision. Assessment of tumour status was performed every 6 weeks through week 25, every 9 weeks through week 52 and every 12 weeks thereafter. After a median follow-up of 30&nbsp;months, 6 out of 53 patients randomised to dostarlimab plus carboplatin-paclitaxel have received treatment for &gt;3 years (cut-off date 01 Mar 2023).</p><p>The key eligibility criteria for the study were International Federation of Gynaecology and Obstetrics (FIGO) primary Stage III or Stage IV disease, including Stage IIIA to IIIC1 disease with presence of evaluable or measurable disease per RECIST v.1.1, Stage IIIC1 patients with carcinosarcoma, clear cell, serous, or mixed histology (containing &ge;10% carcinosarcoma, clear cell, or serous histology) regardless of presence of evaluable or measurable disease on imaging, Stage IIIC2 or Stage IV disease regardless of presence of evaluable or measurable disease. The study also included patients with first recurrent EC with a low potential for cure by radiation therapy or surgery alone or in combination, including patients who had first recurrent disease and were na&iuml;ve to systemic anticancer therapy or who had received prior neo-adjuvant/adjuvant systemic anticancer therapy and had a recurrence or progressive disease &ge;6 months after completing treatment (first recurrence). Prior radiation was not permitted within 21 days of study treatment excluding palliative radiotherapy which was permitted within up to 1 week of study treatment.</p><p>The primary efficacy outcome measures were progression-free survival (PFS) assessed by the investigator according to RECIST v1.1 in subjects with dMMR/MSI-H primary advanced or recurrent EC and in all subjects (overall ITT population) with primary advanced or recurrent EC, and overall survival (OS) in all subjects (overall ITT population) with primary advanced or recurrent EC.&nbsp;</p><p>A total of 118&nbsp;patients with dMMR/MSI-H EC were evaluated for efficacy in the RUBY study. Baseline demographics and characteristics were: median age 64 years (34% aged 65 to 74 years and 15% aged 75 years or older); 85% White, 9% Black, 2% Asian; ECOG PS 0 (57%) or 1 (43%); primary stage III 21%, primary stage IV 30%, recurrent EC 49%; endometrioid carcinoma 85%, mixed carcinoma 5%, carcinosarcoma 4%, serous carcinoma 2%, other 4%; and prior surgery 92%, prior radiotherapy (35%), prior anti-cancer therapy (14%).</p><p>The identification of dMMR/MSI-H tumour status was prospectively determined based on local testing assays (IHC, PCR or NGS), or central testing (IHC) when no local result was available.</p><p>Efficacy results are shown in Table&nbsp;5 and Figure 1. All endpoints are presented at the primary analysis for PFS with median follow up of 25 months. OS results are based on the first OS interim analysis. The RUBY study demonstrated a statistically significant improvement in PFS by investigator in patients randomised to dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel.</p><p><strong>Table&nbsp;5: Efficacy results in RUBY for patients with dMMR/MSI-H EC</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:567px"><thead><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Dostarlimab + carboplatin-paclitaxel</strong></p><p><strong>(N=53)</strong><sup>a</sup></p></td><td style="vertical-align:top"><p><strong>Placebo + carboplatin-paclitaxel</strong></p><p><strong>(N=65)</strong><sup>a</sup></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Progression free-survival (PFS)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median in months (95% CI)<sup>b</sup></p></td><td style="vertical-align:top"><p>Not reached</p></td><td style="vertical-align:top"><p>7.7 (5.6, 9.7)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number (%) of patients with event</p></td><td style="vertical-align:top"><p>19 (35.8)</p></td><td style="vertical-align:top"><p>47 (72.3)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (95% CI)<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.28 (0.16, 0.50)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall survival (OS)</strong><sup>d</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median in months</p></td><td style="vertical-align:top"><p>Not reached</p></td><td style="vertical-align:top"><p>Not reached</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number (%) of patients with event</p></td><td style="vertical-align:top"><p>7 (13.2)</p></td><td style="vertical-align:top"><p>24 (36.9)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (95% CI)<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.30 (0.13, 0.70)</p></td></tr></tbody></table><p>CI: Confidence interval</p><p><sup>a</sup> Efficacy data with a median follow-up of 25 months (cut-off date 28 Sept 2022).<br /><sup>b</sup> One-sided p-value based on stratified log-rank test.</p><p><sup>c</sup> Based on stratified Cox regression model.</p><p><sup>d</sup> Not statistically significant since no hypothesis testing was performed for overall survival in the dMMR/MSI-H population.</p><p><strong>Figure&nbsp;1: Kaplan-Meier curve of progression‑free survival per investigator assessment in patients with </strong><strong>dMMR</strong><strong>/MSI-H</strong><strong> </strong><strong>EC (RUBY study)</strong></p><p><img src="data:image/png;base64,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" alt="" width="900" height="471" vspace="0" hspace="0" border="0" style="width:900px;height:471px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><br /><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><em>GARNET: adult </em><em>patients with recurrent or advanced</em> <em>dMMR/MSI-H EC who have progressed on or after treatment with a platinum-containing regimen</em></p><p>The efficacy and safety of dostarlimab monotherapy were investigated in the GARNET study, a multicentre, uncontrolled, multiple parallel cohort, open-label study. The GARNET study included expansion cohorts in subjects with recurrent or advanced solid tumours who have limited available treatment options. Cohort&nbsp;A1 enrolled patients with dMMR/ MSI-H EC who have progressed on or after a platinum‑containing regimen.</p><p>Patients received 500&nbsp;mg dostarlimab every 3&nbsp;weeks for 4&nbsp;cycles followed by 1000&nbsp;mg dostarlimab every 6&nbsp;weeks. Treatment continued until unacceptable toxicity or disease progression for up to two&nbsp;years.</p><p>The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR) as assessed by blinded independent central radiologists&rsquo; (BICR) review according to response evaluation criteria in solid tumours (RECIST) v&nbsp;1.1. The efficacy population was defined as patients who had measurable disease by BICR at baseline and had minimum of 24&nbsp;weeks follow-up or had less than 24 weeks of follow-up and discontinued due to adverse events or disease progression.</p><p>A total of 143 patients with dMMR/MSI‑H EC were evaluated for efficacy in the GARNET study.</p><p>Among these 143 patients, the baseline characteristics were: median age of 65&nbsp;years (52&nbsp;% aged 65&nbsp;years or older); 77&nbsp;% white, 3.5&nbsp;% Asian, 2.8&nbsp;% black; and ECOGPS 0 (39&nbsp;%) or 1 (61&nbsp;%). At the time of diagnosis, 21&nbsp;% of the patients with dMMR/MSI‑H EC were FIGO Stage&nbsp;IV. At study entry (the most recent FIGO stage), 67&nbsp;% of the patients were FIGO Stage&nbsp;IV. The median number of prior lines of therapy was one: 63&nbsp;% of patients had one prior line, 37&nbsp;% had two or more prior lines. Forty-nine patients (34&nbsp;%) received treatment only in the neoadjuvant or adjuvant setting before participating in the study.</p><p>The identification of dMMR/MSI‑H tumour status was prospectively determined based on local testing.</p><p>Local diagnostic assays (IHC, PCR or NGS) available at the sites were used for the detection of the dMMR/MSI-H expression in tumour material. Most of the sites used IHC as it was the most common assay available.</p><p>Table&nbsp;6 includes the efficacy data for the&nbsp;143 patients. The overall median treatment duration in weeks was 34 (range 2 to 220). &nbsp;Twenty four percent of subjects who received any amount of dostarlimab received treatment &gt;102 weeks (2 years).</p><p>&nbsp;</p><p><strong>Table&nbsp;6: Efficacy results in GARNET for patients with dMMR/MSI-H EC</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:576px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Results</strong></p><p><strong>(N=143)</strong><sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate (ORR)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORR n (%)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (95&nbsp;% CI)</p></td><td style="vertical-align:top"><p>65 (45.5)</p><p>(37.1, 54.0)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete response rate, n (%)</p></td><td style="vertical-align:top"><p>23 (16.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Partial response rate, n (%)</p></td><td style="vertical-align:top"><p>42 (29.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response (DOR)</strong><sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median in months</p></td><td style="vertical-align:top"><p>Not reached</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with duration &ge; 12 months, n (%)</p></td><td style="vertical-align:top"><p>52 (80.0)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with duration &ge; 24 months, n (%)</p></td><td style="vertical-align:top"><p>29 (44.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Disease control rate (DCR)</strong><sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DCR n (%)<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (95&nbsp;% CI)</p></td><td style="vertical-align:top"><p>86 (60.1)<br />(51.6, 68.2)</p></td></tr></tbody></table><p>CI: Confidence interval</p><p><sup>a</sup> Efficacy data with a median follow-up of 27.6 months (cut-off date 01 Nov 2021)<br /><sup>b</sup> For patients with a partial or complete response.</p><p><sup>c</sup> includes patient with complete response, partial response and stable disease for at least 12 weeks.</p><p><u>Efficacy and PD-L1 status</u></p><p>Clinical activity was observed regardless of tumour PD-L1 combined positive score (CPS) by IHC. The relationship between PD-L1 status and efficacy was analysed post-hoc in patients with available tissue samples (N&nbsp;=&nbsp;81) among the efficacy population from Cohort&nbsp;A1 of the GARNET study using a data cut-off date of 01&nbsp;March&nbsp;2020. Among 23&nbsp;patients with PD-L1 CPS &lt;&nbsp;1&nbsp;%, ORR was 30.4&nbsp;% (7/23, 95&nbsp;% CI&nbsp;13.2, 52.9) and among 58&nbsp;patients with PD-L1 CPS &ge;&nbsp;1&nbsp;%, ORR was 55.2&nbsp;% (32/58, 95&nbsp;% CI 41.5, 68.3).</p><p><u>Elderly patients</u></p><p>Of the 108&nbsp;patients treated with dostarlimab in the GARNET study efficacy population, 50.0 % were older than 65&nbsp;years.</p><p>Consistent results were observed in the elderly population, where the ORR by BICR (95%&nbsp;CI) was 42.6&nbsp;% (29.2&nbsp;%, 56.8&nbsp;%) in patients &ge;&nbsp;65 years.</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with dostarlimab in all subsets of the paediatric population in the treatment of all conditions included in the category of malignant neoplasms, except haematopoietic and lymphoid tissue (see section 4.2 for information on paediatric use).<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_0a0da859-fdbb-4cf5-aece-4ccc01874a8b \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span style='mso-element:
field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics (PK) of dostarlimab were assessed as a monotherapy and when administered in combination with carboplatin and paclitaxel.<!--[if supportFields]><span lang=EN-US style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-US;mso-bidi-font-weight:bold;mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b649ece4-479c-4a01-96b7-7472a2fe257a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-US style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US;mso-bidi-font-weight:
bold;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Dostarlimab monotherapy or in combination with carboplatin and paclitaxel was characterised using population PK analysis from 869&nbsp;patients with various solid tumours, including 546&nbsp;patients with EC. When dosed at the recommended therapeutic dose for monotherapy (500&nbsp;mg administered intravenously every 3&nbsp;weeks for 4&nbsp;doses, followed by 1,000&nbsp;mg every 6&nbsp;weeks), or at the recommended therapeutic dose for combination with carboplatin and paclitaxel (500 mg administered intravenously every 3 weeks for 6 doses, followed by 1000 mg every 6 weeks), dostarlimab shows an approximate two‑fold accumulation (C<sub>min</sub>), consistent with the terminal half‑life (t<sub>1/2</sub>).<!--[if supportFields]><span
style='mso-element:field-begin'></span>DOCVARIABLE
vault_nd_8cf480a5-8602-40bc-a2e1-4eb7f670ffa3 \* MERGEFORMAT<span
style='mso-element:field-separator'></span><![endif]--> <!--[if supportFields]><span
lang=EN-US style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US;mso-bidi-font-weight:
bold;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]-->&nbsp;The exposure of dostarlimab as monotherapy and/or in combination with carboplatin and paclitaxel was similar.</p><p><u>Absorption</u></p><p>Dostarlimab is administered via the intravenous route and therefore estimates of absorption are not applicable.</p><p><u>Distribution</u></p><p>The mean volume of distribution of dostarlimab at steady state is approximately 5.8&nbsp;L (CV&nbsp;% of 14.9&nbsp;%).</p><p><u>Biotransformation</u></p><p>Dostarlimab is a therapeutic mAb IgG4 that is expected to be catabolised into small peptides, amino acids, and small carbohydrates by lysosome through fluid‑phase or receptor‑mediated endocytosis. The degradation products are eliminated by renal excretion or returned to the nutrient pool without biological effects.</p><p><u>Elimination</u></p><p>The mean clearance is 0.007&nbsp;L/h (CV&nbsp;% of 30.2&nbsp;%) at steady state. The t<sub>1/2</sub> at steady state is 23.2&nbsp;days (CV&nbsp;% of 20.8&nbsp;%).</p><p>Dostarlimab clearance was estimated to be 7.8% lower when dostarlimab was given in combination with carboplatin and paclitaxel. There was no meaningful impact on dostarlimab exposure.</p><p><u>Linearity/non‑linearity</u></p><p>Exposure (both maximum concentration [C<sub>max</sub>] and the area under the concentration‑time curve, [AUC<sub>0-tau</sub>] and [AUC<sub>0-inf</sub>]) was approximately dose proportional.</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>Based on exposure efficacy and safety relationships, there are no clinically significant differences in efficacy and safety when doubling the exposure of dostarlimab. Full receptor occupancy as measured by both the direct PD‑1 binding and interleukin 2 (IL‑2) production functional assay was maintained throughout the dosing interval at the recommended therapeutic dosing regimen.</p><p><u>Special populations</u></p><p>A population PK analysis of the patient data indicates that there are no clinically important effects of age (range: 24 to 86&nbsp;years), gender or race, ethnicity, or tumour type on the clearance of dostarlimab.</p><p><u>Renal impairment</u></p><p>Renal impairment was evaluated based on the estimated creatinine clearance [CL<sub>CR</sub>&nbsp;mL/min] (normal: CL<sub>CR</sub> &ge; 90&nbsp;mL/min, n&nbsp;=&nbsp;305; mild: CL<sub>CR&nbsp;</sub>=&nbsp;60‑89&nbsp;mL/min, n&nbsp;=&nbsp;397; moderate: CL<sub>CR</sub>&nbsp;=&nbsp;30‑59&nbsp;mL/min, n&nbsp;=&nbsp;164; severe: CL<sub>CR</sub>&nbsp;=&nbsp;15‑29&nbsp;mL/min, n&nbsp;=&nbsp;3 and ESRD: CL<sub>CR&nbsp;</sub>&lt;&nbsp;15&nbsp;mL/min, n&nbsp;=&nbsp;1). The effect of renal impairment on the clearance of dostarlimab was evaluated by population pharmacokinetic analyses in patients with mild or moderate renal impairment compared to patients with normal renal function. No clinically important differences in the clearance of dostarlimab were found between patients with mild or moderate renal impairment and patients with normal renal function. There are limited data in patients with severe renal impairment.</p><p><u>Hepatic impairment</u></p><p>Hepatic impairment was evaluated as defined using the US National Cancer Institute criteria of hepatic dysfunction by total bilirubin and AST (Normal: total bilirubin (TB) &amp; AST &lt;&nbsp;= upper limit of normal (ULN), n&nbsp;=&nbsp;772; mild: TB&nbsp;&gt;&nbsp;ULN to 1.5&nbsp;ULN or AST&nbsp;&gt;&nbsp;ULN, n&nbsp;=&nbsp;92; and moderate: TB&nbsp;&gt;&nbsp;1.5‑3&nbsp;ULN, any AST, n&nbsp;=&nbsp;5). The effect of hepatic impairment on the clearance of dostarlimab was evaluated by population pharmacokinetic analyses in patients with mild hepatic impairment compared to patients with normal hepatic function. No clinically important differences in the clearance of dostarlimab were found between patients with mild hepatic impairment and normal hepatic function. There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical data reveal no special hazard for humans based on repeat‑dose toxicity studies of duration up to 3 months in the cynomolgus monkey. No studies have been performed to assess the potential of dostarlimab for carcinogenicity or genotoxicity. Animal reproduction and development toxicity studies have not been conducted with dostarlimab. Blockade of PD‑L1 signaling has been shown in murine models of pregnancy to disrupt tolerance to the foetus and to result in an increase in foetal loss. These results indicate a potential risk that administration of dostarlimab during pregnancy could cause foetal harm, including increased rates of abortion or stillbirth.</p><p>No notable effects on the male and female reproductive organs were observed in monkeys in the 1‑month and 3‑month repeat‑dose toxicology studies; however, these results may not be representative at all of the potential clinical risk because of the immaturity of the reproductive system of animals used in the studies. Therefore, fertility toxicity remains unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trisodium citrate dihydrate</p><p>Citric acid monohydrate</p><p>L‑arginine hydrochloride</p><p>Sodium chloride</p><p>Polysorbate 80</p><p>Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
3 years.
After dilution
If not used immediately, chemical and physical in-use stability has been demonstrated for 24 hours at 2 °C – 8 °C and 6 hours at room temperature (up to 25 °C) from the time of preparation/dilution until the end of administration. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator 2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C.</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions after dilution of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10&nbsp;mL type&nbsp;I borosilicate clear glass vial, with a grey chlorobutyl elastomer stopper laminated with fluoropolymer, sealed with an aluminium flip‑off cap containing 500&nbsp;mg dostarlimab.</p><p>Each carton contains one vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Preparation/dilution</u></p><p>Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. JEMPERLI is a slightly opalescent colourless to yellow solution. Discard the vial if visible particles are observed.</p><p>JEMPERLI is compatible with an IV bag made of polyvinyl chloride (PVC) with or without di(2-ethylhexyl) phthalate (DEHP), ethylene vinyl acetate, polyethylene (PE), polypropylene (PP) or polyolefin blend (PP+PE), and a syringe made from PP.</p><p>For the 500&nbsp;mg dose, withdraw 10&nbsp;mL of JEMPERLI from a vial and transfer into an intravenous bag containing sodium chloride 9&nbsp;mg/mL (0.9&nbsp;%) solution for injection, or glucose 50&nbsp;mg/mL (5&nbsp;%) solution for injection. The final concentration of the diluted solution should be between 2&nbsp;mg/mL and 10&nbsp;mg/mL. This may require withdrawing a volume of diluent from the intravenous bag prior to adding a volume of JEMPERLI into the IV bag.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; For example, if preparing a 500 mg dose in a 250 mL diluent intravenous bag, to achieve a 2&nbsp;mg/mL concentration would require withdrawing 10 mL of diluent from the 250 mL intravenous bag. Then, 10 mL of JEMPERLI would be withdrawn from the vial and transferred into the intravenous bag.</p><p>For the 1000&nbsp;mg dose, withdraw 10&nbsp;mL of JEMPERLI from each of two vials (withdraw 20&nbsp;mL total) and transfer into an intravenous bag containing sodium chloride 9&nbsp;mg/mL (0.9&nbsp;%) solution for injection, or glucose 50&nbsp;mg/mL (5&nbsp;%) solution for injection. The final concentration of the diluted solution should be between 2&nbsp;mg/mL and 10&nbsp;mg/mL. This may require withdrawing a volume of diluent from the IV bag prior to adding a volume of JEMPERLI into the intravenous bag.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; For example, if preparing a 1000 mg dose in a 500 mL diluent intravenous bag, to achieve a 2&nbsp;mg/mL concentration would require withdrawing 20 mL of diluent from the 500 mL intravenous bag. Then, 10 mL of JEMPERLI would be withdrawn from each of two vials, totaling 20 mL, and transferred into the intravenous bag.</p><p>Mix diluted solution by gentle inversion. Do not shake the final infusion bag. Discard any unused portion left in the vial.</p><p><u>Storage</u></p><p>Store in the original carton until time of preparation in order to protect from light. The prepared dose may be stored either:</p><p>-&nbsp;&nbsp;&nbsp; At room temperature up to 25&nbsp;&ordm;C for no more than 6&nbsp;hours from the time of dilution until the end of infusion.</p><p>-&nbsp; Under refrigeration at 2&nbsp;&deg;C to 8&nbsp;&deg;C for no more than 24&nbsp;hours from time of dilution until end of infusion. If refrigerated, allow the diluted solution to come to room temperature prior to administration.</p><p><u>Administration</u></p><p>JEMPERLI should be administered by intravenous infusion using an intravenous infusion pump over 30&nbsp;minutes by a health care practitioner.<em> </em>Tubing should be made of PVC, platinum cured silicon or PP; fittings made from PVC or polycarbonate and needles made from stainless steel. A 0.2 or 0.22 micron in-line polyethersulfone (PES) filter must be used during administration of JEMPERLI.</p><p>JEMPERLI must not be administered as an intravenous push or bolus injection.</p><p>Do not co‑administer other medicinal products through the same infusion line.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><strong><em>Jemperli</em></strong><strong> </strong>is a trademark owned by or licensed to GSK group of companies.</p><p>&copy; 2024 GSK group of companies. All rights reserved</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Ajinomoto Althea, Inc.(dba Ajinomoto Bio-Pharma Services), 11040 Roselle Street, San Diego, CA 92121, USA
Packed by:
Packaging Coordinators, LLC, 3001 Red Lion Road, Philadelphia, PA, 19114, USA

Release by:
GlaxoSmithKline LLC, 1011 North Arendell, Avenue, Zebulon, NC 27597, USA
Marketing Authorization Holder:
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia
*member of the GlaxoSmithKline group of companies
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: EMA-v08 
Date of revision of the text: 07 December 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>